Recent evidence has demonstrated that this oxidative stress induced during HCV infection via mitochondrial dysfunction generates ROS (Choi and Ou, 2006). High serum, plasma, erythrocyte and PBMC concentrations of MDA, 4-HNE, and F2-isoprostanes, in combination with decreased levels of the antioxidant enzymes catalase, superoxide dismutase (SOD) and glutathione peroxidase (GPx), and decreased glutathione (GSH) and ascorbic acid (vitamin C) levels could reflect mitochondrial dysfunction (Wiswedel et al., 2002; Wen et al., 2006; Gomez-Cabrera et al., 2008; Sahach et al., 2008). The determination of serum, plasma, erythrocyte, urine, and PBMC concentrations of oxidative stress markers serves as an indirect index of mitochondrial oxidative stress in pathologic conditions (Modica-Napolitano et al., 2007). However, few studies have elucidated clinical importance of mitochondrial oxidative damage in chronic hepatitis C.

### **4. Mitochondria-driven free radical propagation**

238 Antioxidant Enzyme

**2. Chronic Hepatitis C**

viral load (Ghany et al., 2009).

al., 2009; West et al., 2011).

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. HCV infection frequently does not resolve, leading to chronic hepatitis with increasing risk of developing hepatic fibrosis, steatosis, liver cirrhosis, hepatocellular carcinoma, and extrahepatic diseases (Choi and Ou, 2006). The combination of pegylated interferon (IFN)-a and ribavirin is the only treatment for chronic HCV infections with proven efficacy. Unfortunately, this therapeutic strategy results in a low sustained virologic response (SVR), defined as an absence of detectable serum HCV-RNA at six months after completion of antiviral therapy; SVR is achieved in less than 50% of treated patients that have HCV genotype 1 and a high

There is evidence indicating that SVR is associated with long-term clearance of HCV infection and lower HCV-related complications (Ghany et al., 2011; Pearlman and Traub, 2011). However, IFN-a in combination with ribavirin is generally not well tolerated, and the adverse side effects may lead to interruption or cessation of therapy. The major adverse effects are anemia, fatigue, hair loss, depression, insomnia, vertigo, anorexia, nausea, nasal congestion, cough, dyspnea, pruritus, and growth delay (Ko et al., 2005a). Thus, further

Recent studies indicate that oxidative stress not only accelerates the progression of liver damage (Vidali et al., 2008), but also affects the immune response to HCV infection and decreases SVR (Onoda et al., 2004; Polyak et al., 2007). Altered innate immunity (i.e., NK cells, neutrophils, dendritic cells, monocytes, and macrophages) and adaptive immunity (Tand B-lymphocytes) have influences in the development and progression of HCV infection. Although innate immunity can regulate adaptive immune response, HCV may escapes innate immune sensing by Toll-like receptors and acerbates HCV infection and replication (Zhang et al., 2006; Montero Vega and de Andrés Martín, 2008). Thus, this sometimes makes it difficult for the immune response to suppress or eliminate HCV. The imbalance between cell-mediated and humoral immunity in chronic HCV-infected patients was also observed. Insufficient helper (CD4) and cytotoxic (CD8) T-lymphocytes have been shown significantly linked to HCV persistence (Grüngreiff and Reinhold, 2010). Recent evidence has shown that damaging ROS and mitochondrial injury play a vital role in immune responses (Kohchi et

Further, potential risk factors associated with SVR in HCV-infected patients include baseline HCV-RNA and aminotransferase levels, obesity, alcohol, insulin resistance (IR), nonalcoholic fatty liver disease (NAFLD), and fibrosis stage (Yamada et al., 2008; Pillai et al., 2010). In particular, NAFLD is not only strongly associated with IR and metabolic syndrome, but also with chronic HCV infection. The presence of hepatic steatosis correlates directly with serum and intra-hepatic titers of HCV-RNA (Younossi et al., 2004; Hübscher, 2006). Hepatic stellate cells can be activated by pro-inflammatory cytokines thus contributed

advances in effective antiviral treatments against chronic hepatitis C are necessary.

**3. Oxidative stress and related risk factors in chronic Hepatitis C**

Not only are mitochondria the source of adenosine triphosphate (ATP) through oxidative phosphorylation on the inner mitochondrial membrane, but also the target of potentially damaging free radicals (Orrenius et al., 2007). Mitochondrial energy generation is first accomplished by tricarboxylic acid (TCA) cycle and represented in the form of ATP, nicotinamide adenine dinucleotide (NADH) and reduced flavin adenine dinucleotide (FADH2). Furthermore, oxidative phosphorylation is the primary energy process by which the oxidoreduction energy of mitochondrial electron transport is converted to the highenergy phosphate bond of ATP. Oxygen (O2) serves as the terminal electron acceptor for cytochrome c oxidase of complex IV in the mitochondrial electron transport chain (ETC) that catalyzes the four electrons reduction of O2 to H2O (Thannickal and Fanburg, 2000).

Coenzyme Q (CoQ, ubiquinone) behaves as an electron pool and a mediator of the electron transport between complex II (succinate dehydrogenase; also referred to as FADH2: succinate CoQ reductase) and complex III (ubiquinone-cytochrome c reductase) with complex I (NADH dehydrogenase; also referred to as NADH: ubiquinone oxidoreductase). A decrease in CoQ concentrations, activated reverse electron transfer, decline in the electron transport rate, or inhibition of electron flow can result in high-energy electrons leaking from the ETC at complexes I, II, III, and IV to produce O2**\***- (Lenaz et al., 2007). The major production site of O2**\*** is reportedly complexes I and III. Complex I produces O2**\*** predominantly on the matrix side of the inner membrane, whereas complex III-derived O2**\*** is produced both towards the inner-membrane space and the matrix (Matsuzaki et al., 2009). In particular, the matrix contains the components of the TCA cycle and fatty acid βoxidation pathway, as well as mitochondrial deoxyribonucleic acid (mtDNA). The mtDNA is also a critical target for oxidative damage. Once damaged, mDNA can amplify the secondary ROS generation (Van Houten et al., 2006). It appears that mitochondria are the organelle responsible for the majority of ROS production.

Mitochondrial Free Radicals, Antioxidants, Nutrient Substances, and Chronic Hepatitis C 241

to form highly reactive single oxygen.

As illustrated in the equations below, O2\*- can either spontaneously dismute to H2O2 by reacting with itself or O2\*- can be catalyzed by antioxidant enzymes. Because the mitochondrial membrane is permeable to H2O2, hydrogen peroxide can diffuse into the cytoplasm. H2O2 also decomposes to form the highly reactive hydroxyl radical, and this decomposition is accelerated in the presence of either ferrous or cuprous ions (Cu+).

**2 O2\* – + 2H+ → H2O2 + O2** (i.e., the dismutation reaction of superoxide)

**O2\* – + Fe+3 → O2 + Fe+2**

Increased free radicals generated by damaged mitochondria can cause oxidative damage and a significant decline in metabolic processes; increase the mitochondrial membrane potential; impair the flow of electrons along the ETC; decrease mitochondrial membrane fluidity; decrease respiratory control ratios and cellular oxygen consumption; oxidate cardiolipin (a phospholipid and located at both the inner and outer membranes); deplete cytochrome c; induce cellular calcium (Ca+2) dyshomeostasis; and produce high levels of unwanted oxidants (Mecocci et al., 1997; Petrosillo et al., 2003; Mei et al., 2012; Nowak et al., 2012). The inevitable by-products of oxidative phosphorylation can modify and damage mtDNA, proteins, lipid, and matrix components in the mitochondria, as well as deplete

Mitochondrial membranes are primarily composed of protein and phospholipids, whose interdependence is crucial for mitochondrial function (Gohil and Greenberg, 2009). In particular, fatty acids of the inner membrane are highly unsaturated (Berdanier, 1988). ROS attack to the mitochondrial membrane lipid components result in lipid peroxidation, which alter the membrane potential (Paradies et al., 2004). Therefore, ROS-induced mitochondrial damage that is considered an important mechanism involved in the onset and development

A network of specific non-enzymatic and enzymatic antioxidants can counteract mitochondrial ROS generation. Among these antioxidants, the non-enzymatic antioxidant systems are the second line of defense against free radical damage. It has been known that non-enzymatic antioxidants can act synergistically with enzymatic antioxidants. In animal models, administration of antioxidant vitamins increases mitochondrial SOD, GPx and catalase activity and significantly decreases MDA and carbonyl group levels, and thus

**O2\* – + OH\* → 1O2\***

 **+ OH-**

 **+ OH-**

; **(Cu+ → Cu+2)**

**Fe+2 + H2O2 → Fe+3 + OH\***

cellular antioxidants, which all lead to cell death (Marchi et al., 2012).

of a diverse series of pathologies.

**5. Enzymatic antioxidants in mitochondria**

**4.2. Consequences of mitochondrial oxidative stress**

Moreover, superoxide can react with the radical OH**\***

It is also noteworthy that self-amplification of the mitochondrial ROS generation can occur following ROS activation of mitochondrial permeability transition pore (MPTP). Once MPTP opening is triggered, ROS can induce the simultaneous collapse of the mitochondrial membrane potential (Δѱ, Dym) and a further increase in ROS generation by the ETC (Andreyev et al., 2005). In addition, damaged mitochondria produce increasingly more ROS in a process known as ROS-induced ROS release (RIRR) activation. In turn, cytosolic ROS released from the mitochondria could potentially function as second messengers to activate RIRR in neighboring mitochondria (Zorov et al., 2006).

### **4.1. Mitochondrial oxidant production**

O2**\*-** is the initial ROS generated in mitochondria during oxidative phosphorylation. Leakage of electrons from the mitochondrial ETC can result in incomplete reduction of molecular oxygen to produce O2**\*-**. The O2**\*-** itself is not particularly reactive in biological systems; however, O2**\*-** anions can damage heme moieties or enzymes with iron-sulfur centers such as aconitase ([4Fe-4S]**→**[3Fe-4S]+) to release ferrous ion (Fe+2)(Ott et al., 2007). The Fe+2 can subsequently react with H2O2 to generate hydroxyl radicals (i.e., a Fenton process). Those superoxide radical anions can also react with NO**\*** to form the damaging oxidant ONOO- , which is more reactive than either precursor (Barber et al., 2006). In turn, hydroxyl radical and nitric dioxide can be produced from ONOO- , and membrane lipid peroxidation and nitration of proteins on tyrosine residues are promoted (Beckman and Crow, 1993). ONOOfurther damages complex I, II, and V as well as mitochondrial SOD, GPx, and aconitase (Holley et al., 2011). A growing body of evidence demonstrates that NO diffuses easily along its gradient into mitochondria and that NO is also produced by mitochondria (Alvarez et al., 2003). The above-described reactions are summarized in the following equations:

**O2 (in mitochondria) + e- → O2\*-**

**O2\*- + NO\* (in mitochondria) → ONOO–**

> **ONOO– + H+ → OH\* + NO2\***

As illustrated in the equations below, O2\*- can either spontaneously dismute to H2O2 by reacting with itself or O2\*- can be catalyzed by antioxidant enzymes. Because the mitochondrial membrane is permeable to H2O2, hydrogen peroxide can diffuse into the cytoplasm. H2O2 also decomposes to form the highly reactive hydroxyl radical, and this decomposition is accelerated in the presence of either ferrous or cuprous ions (Cu+). Moreover, superoxide can react with the radical OH**\*** to form highly reactive single oxygen.

**2 O2\* – + 2H+ → H2O2 + O2** (i.e., the dismutation reaction of superoxide)

**O2\* – + Fe+3 → O2 + Fe+2 Fe+2 + H2O2 → Fe+3 + OH\* + OH-** ; **(Cu+ → Cu+2) O2\* – + OH\* → 1O2\* + OH-**

### **4.2. Consequences of mitochondrial oxidative stress**

240 Antioxidant Enzyme

production site of O2**\***-

A decrease in CoQ concentrations, activated reverse electron transfer, decline in the electron transport rate, or inhibition of electron flow can result in high-energy electrons leaking from

predominantly on the matrix side of the inner membrane, whereas complex III-derived O2**\*** is produced both towards the inner-membrane space and the matrix (Matsuzaki et al., 2009). In particular, the matrix contains the components of the TCA cycle and fatty acid βoxidation pathway, as well as mitochondrial deoxyribonucleic acid (mtDNA). The mtDNA is also a critical target for oxidative damage. Once damaged, mDNA can amplify the secondary ROS generation (Van Houten et al., 2006). It appears that mitochondria are the

It is also noteworthy that self-amplification of the mitochondrial ROS generation can occur following ROS activation of mitochondrial permeability transition pore (MPTP). Once MPTP opening is triggered, ROS can induce the simultaneous collapse of the mitochondrial membrane potential (Δѱ, Dym) and a further increase in ROS generation by the ETC (Andreyev et al., 2005). In addition, damaged mitochondria produce increasingly more ROS in a process known as ROS-induced ROS release (RIRR) activation. In turn, cytosolic ROS released from the mitochondria could potentially function as second messengers to activate

O2**\*-** is the initial ROS generated in mitochondria during oxidative phosphorylation. Leakage of electrons from the mitochondrial ETC can result in incomplete reduction of molecular oxygen to produce O2**\*-**. The O2**\*-** itself is not particularly reactive in biological systems; however, O2**\*-** anions can damage heme moieties or enzymes with iron-sulfur centers such as aconitase ([4Fe-4S]**→**[3Fe-4S]+) to release ferrous ion (Fe+2)(Ott et al., 2007). The Fe+2 can subsequently react with H2O2 to generate hydroxyl radicals (i.e., a Fenton process). Those

which is more reactive than either precursor (Barber et al., 2006). In turn, hydroxyl radical

nitration of proteins on tyrosine residues are promoted (Beckman and Crow, 1993). ONOOfurther damages complex I, II, and V as well as mitochondrial SOD, GPx, and aconitase (Holley et al., 2011). A growing body of evidence demonstrates that NO diffuses easily along its gradient into mitochondria and that NO is also produced by mitochondria (Alvarez et al., 2003). The above-described reactions are summarized in the following

**O2 (in mitochondria) + e- → O2\*-**

**ONOO– + H+ → OH\***

 **(in mitochondria) → ONOO–**

 **+ NO2\***

is reportedly complexes I and III. Complex I produces O2**\***-

(Lenaz et al., 2007). The major

to form the damaging oxidant ONOO-

, and membrane lipid peroxidation and

,

the ETC at complexes I, II, III, and IV to produce O2**\***-

organelle responsible for the majority of ROS production.

RIRR in neighboring mitochondria (Zorov et al., 2006).

superoxide radical anions can also react with NO**\***

and nitric dioxide can be produced from ONOO-

**O2\*- + NO\***

equations:

**4.1. Mitochondrial oxidant production**

Increased free radicals generated by damaged mitochondria can cause oxidative damage and a significant decline in metabolic processes; increase the mitochondrial membrane potential; impair the flow of electrons along the ETC; decrease mitochondrial membrane fluidity; decrease respiratory control ratios and cellular oxygen consumption; oxidate cardiolipin (a phospholipid and located at both the inner and outer membranes); deplete cytochrome c; induce cellular calcium (Ca+2) dyshomeostasis; and produce high levels of unwanted oxidants (Mecocci et al., 1997; Petrosillo et al., 2003; Mei et al., 2012; Nowak et al., 2012). The inevitable by-products of oxidative phosphorylation can modify and damage mtDNA, proteins, lipid, and matrix components in the mitochondria, as well as deplete cellular antioxidants, which all lead to cell death (Marchi et al., 2012).

Mitochondrial membranes are primarily composed of protein and phospholipids, whose interdependence is crucial for mitochondrial function (Gohil and Greenberg, 2009). In particular, fatty acids of the inner membrane are highly unsaturated (Berdanier, 1988). ROS attack to the mitochondrial membrane lipid components result in lipid peroxidation, which alter the membrane potential (Paradies et al., 2004). Therefore, ROS-induced mitochondrial damage that is considered an important mechanism involved in the onset and development of a diverse series of pathologies.

### **5. Enzymatic antioxidants in mitochondria**

A network of specific non-enzymatic and enzymatic antioxidants can counteract mitochondrial ROS generation. Among these antioxidants, the non-enzymatic antioxidant systems are the second line of defense against free radical damage. It has been known that non-enzymatic antioxidants can act synergistically with enzymatic antioxidants. In animal models, administration of antioxidant vitamins increases mitochondrial SOD, GPx and catalase activity and significantly decreases MDA and carbonyl group levels, and thus prevents rupture of mitochondrial membrane (Siler-Marsiglio et al., 2005; Zang et al., 2007; Rosa et al., 2009). The GSH, CoQ, lipoic acid, vitamin C and E are the non-enzymatic components of the antioxidant defense system in mitochondria (Ott et al., 2007; Liu, 2009).

Mitochondrial Free Radicals, Antioxidants, Nutrient Substances, and Chronic Hepatitis C 243

and peroxisomes (Culotta et al., 2006). Thus, while some O2\*- escapes into the intermembrane space from the matrix side of the inner mitochondrial membrane, it can be partially catalyzed to H2O2 by Cu,Zn-SOD. Both trace elements Cu and Zn participate in the SOD enzymatic mechanisms that play an important role in oxidative balance. Apparently, deficiencies of Cu and Zn can result in impairment of the oxidant defense system (i.e., lower Cu,Zn-SOD, catalase, GPx, and cytochrome c oxidase activities), DNA repair, alterations in immune regulation, and increased oxidative stress (Ho and Song, 2009; Song et al., 2009; Guo et al., 2011). Mutations in the mitochondrial Cu,Zn-SOD gene result in SOD that are highly susceptible to glycation and are linked to elevated ROS production (Takamiya et al., 2003). Significantly lower serum and erythrocyte Cu,Zn-SOD activity and higher lipid peroxidation compared to controls have also been observed in patients with mitochondria injury-related disease confitions (Pawlak et al., 2005; Russo, 2009, 2010; Sagdic et al., 2011).

The electron carrier cytochrome c, which is also located in the mitochondrial intermembrane space, oxidizes O2**\*-** back to O2 (Pereverzev et al., 2003). Cytochrome c also scavenges H2O2 and significantly decreases H2O2 production in vitro (Wang et al., 2003). Recent evidence has shown that transgenic mice with overexpressing mutant Cu,Zn-SOD, have significantly decreased levels of inner mitochondrial membrane-associated cytochrome c and increased mitochondrial lipid peroxidation (Kirkinezos et al., 2005). Therefore, Cu,Zn-SOD deletion and the loss of cytochrome c from the mitochondrial inter- membrane space

Selenium (Se)-containing GPx is a selenocysteine-containing enzyme, of which multiple isoforms have been identified, including GPx-1, GPx-2, GPx-3, GPx-4, GPx-5, and GPx-6. GPx-1 is a major isoform localized in the cytoplasm and mitochondrial matrix (Orrenius et al., 2007) that metabolized H2O2 to O2 and H2O. However, GPx-1 levels in mitochondria are very low, compared with those in the cytoplasma. GPx-4 is membrane-associated that is found in the inter-membrane space of mitochondria, and is capable of reducing lipid hydroperoxides, alkyl peroxides, and fatty acid hydroperoxides with protect mitochondrial ATP generation. GPx-4 has also been shown to repair mitochondrial oxidative damage

Se deficiency is associated with marked decreases in GPx activity and expression and the inhibition of ATP production. Patients with low GPx activity, have significant associations with increased levels of MDA, viral infection, and retroviral therapy (Stephensen et al., 2007). GPx can interfere with nuclear factor-kB (NF-kB) activation by IL-1 and TNF-a, inhibit cyclooxygenase-2 (COX-2) expression along with reduce production of arachidonic acid (AA) metabolites, prevent transport of lipid peroxides and oxidative damage, and maintain the mitochondrial oxidative-phosphorylation (Brigelius-Flohé, 2006; Cole-Ezea et al., 2012). Further, lipoproteins synthesis and secretions have been shown to decline by lipid peroxides (Murthy et al., 1998), indicating that activated GPx can attenuate hepatic triglyceride

can lead to reduced ETC and increased O2**\*-** production in disease conditions.

**5.3. Glutathione peroxidase**

(Liang et al., 2009).

accumulation.

The enzymatic antioxidant systems in mitochondria involve SOD, GPx, glutathione reductase (GR), catalase, glutaredoxin, thioredoxin, thioredoxin reductase (TrxR), and peroxiredoxin (PRx). Decreased activity of mitochondrial SOD and GPx were associated with mitochondrial oxidative stress (Zang et al., 2007). In this review, we discuss the characteristics and functions of SOD, GPx, and catalase.

### **5.1. Manganese-dependent superoxide dismutase**

Mn-SOD is highly restricted and located in the mitochondrial matrix. This enzyme is a nuclear- encoded primary antioxidant and plays a vital role in the modulation of redox states. Although the dismutation reaction of O2**\*-** can take place spontaneously, Mn-SOD can accelerate the reaction and rapidly convert O2**\*-** to H2O2. In the equations that follow, both the +2 and +3 states of manganese (Mn) are involved in the course of Mn-SOD turnover and the dismutation cycle.

**Mn+3 -SOD + O2\*- → Mn+2 -SOD + O2**

### **Mn+2 -SOD +O2\*- + 2H+ → Mn+3 -SOD + H2O2**

Mn-SOD not only suppresses ONOO production and tyrosine residue nitration, but also inhibits membrane lipid peroxidation and mtDNA damage (Stojanović et al., 2005). O2**\*-** has a pro-inflammatory role and induces ONOO formation, lipid peroxidation, and recruitment of neutrophils to sites of inflammation. Mn-SOD can scavenge O2**\*-** and therefore mimics anti-inflammatory agent. Altered Mn-SOD levels and chronic inflammation have been associated with neurodegenerative diseases (Li and Zhou, 2011), metabolic diseases, and liver diseases (Kitada et al., 2011). Additionally, Mn-SOD participates in the mitochondrial repair processes and has a role along with p53 in preventing mitochondrial DNA damage (Bakthavatchalu et al., 2012).

The essential trace element Mn principally supports Mn-SOD activity and is required for a variety of physiological processes. Mn-SOD activity is positively related to the nutritional status of Mn (Luk et al., 2005). Clinical Mn deficiency is not common; however, many patients have decreased Mn levels and marked impairments in insulin sensitivity, glucose tolerance, and lipoprotein metabolism, resulting in decreased Mn-SOD and GPx levels, higher oxidative stress, and high mitochondrial abnormalities (Han et al., 2005; Rodríguez-Rodríguez et al., 2011). Thus, Mn dys-homeostasis may be inactive or decrease Mn-SOD levels, leading to mitochondrial oxidative damage.

### **5.2. Copper, zinc-dependent superoxide dismutase**

A SOD isozyme, similar to cytoplasmic Cu,Zn-SOD, that contains Cu and Zn, is also found localized in the mitochondrial inter-membrane space (Kira et al., 2002), nuclei, lysosomes, and peroxisomes (Culotta et al., 2006). Thus, while some O2\*- escapes into the intermembrane space from the matrix side of the inner mitochondrial membrane, it can be partially catalyzed to H2O2 by Cu,Zn-SOD. Both trace elements Cu and Zn participate in the SOD enzymatic mechanisms that play an important role in oxidative balance. Apparently, deficiencies of Cu and Zn can result in impairment of the oxidant defense system (i.e., lower Cu,Zn-SOD, catalase, GPx, and cytochrome c oxidase activities), DNA repair, alterations in immune regulation, and increased oxidative stress (Ho and Song, 2009; Song et al., 2009; Guo et al., 2011). Mutations in the mitochondrial Cu,Zn-SOD gene result in SOD that are highly susceptible to glycation and are linked to elevated ROS production (Takamiya et al., 2003). Significantly lower serum and erythrocyte Cu,Zn-SOD activity and higher lipid peroxidation compared to controls have also been observed in patients with mitochondria injury-related disease confitions (Pawlak et al., 2005; Russo, 2009, 2010; Sagdic et al., 2011).

The electron carrier cytochrome c, which is also located in the mitochondrial intermembrane space, oxidizes O2**\*-** back to O2 (Pereverzev et al., 2003). Cytochrome c also scavenges H2O2 and significantly decreases H2O2 production in vitro (Wang et al., 2003). Recent evidence has shown that transgenic mice with overexpressing mutant Cu,Zn-SOD, have significantly decreased levels of inner mitochondrial membrane-associated cytochrome c and increased mitochondrial lipid peroxidation (Kirkinezos et al., 2005). Therefore, Cu,Zn-SOD deletion and the loss of cytochrome c from the mitochondrial inter- membrane space can lead to reduced ETC and increased O2**\*-** production in disease conditions.

### **5.3. Glutathione peroxidase**

242 Antioxidant Enzyme

the dismutation cycle.

Mn-SOD not only suppresses ONOO-

(Bakthavatchalu et al., 2012).

a pro-inflammatory role and induces ONOO-

levels, leading to mitochondrial oxidative damage.

**5.2. Copper, zinc-dependent superoxide dismutase**

prevents rupture of mitochondrial membrane (Siler-Marsiglio et al., 2005; Zang et al., 2007; Rosa et al., 2009). The GSH, CoQ, lipoic acid, vitamin C and E are the non-enzymatic components of the antioxidant defense system in mitochondria (Ott et al., 2007; Liu, 2009).

The enzymatic antioxidant systems in mitochondria involve SOD, GPx, glutathione reductase (GR), catalase, glutaredoxin, thioredoxin, thioredoxin reductase (TrxR), and peroxiredoxin (PRx). Decreased activity of mitochondrial SOD and GPx were associated with mitochondrial oxidative stress (Zang et al., 2007). In this review, we discuss the

Mn-SOD is highly restricted and located in the mitochondrial matrix. This enzyme is a nuclear- encoded primary antioxidant and plays a vital role in the modulation of redox states. Although the dismutation reaction of O2**\*-** can take place spontaneously, Mn-SOD can accelerate the reaction and rapidly convert O2**\*-** to H2O2. In the equations that follow, both the +2 and +3 states of manganese (Mn) are involved in the course of Mn-SOD turnover and

**Mn+3 -SOD + O2\*- → Mn+2 -SOD + O2**

**Mn+2 -SOD +O2\*- + 2H+ → Mn+3 -SOD + H2O2**

inhibits membrane lipid peroxidation and mtDNA damage (Stojanović et al., 2005). O2**\*-** has

of neutrophils to sites of inflammation. Mn-SOD can scavenge O2**\*-** and therefore mimics anti-inflammatory agent. Altered Mn-SOD levels and chronic inflammation have been associated with neurodegenerative diseases (Li and Zhou, 2011), metabolic diseases, and liver diseases (Kitada et al., 2011). Additionally, Mn-SOD participates in the mitochondrial repair processes and has a role along with p53 in preventing mitochondrial DNA damage

The essential trace element Mn principally supports Mn-SOD activity and is required for a variety of physiological processes. Mn-SOD activity is positively related to the nutritional status of Mn (Luk et al., 2005). Clinical Mn deficiency is not common; however, many patients have decreased Mn levels and marked impairments in insulin sensitivity, glucose tolerance, and lipoprotein metabolism, resulting in decreased Mn-SOD and GPx levels, higher oxidative stress, and high mitochondrial abnormalities (Han et al., 2005; Rodríguez-Rodríguez et al., 2011). Thus, Mn dys-homeostasis may be inactive or decrease Mn-SOD

A SOD isozyme, similar to cytoplasmic Cu,Zn-SOD, that contains Cu and Zn, is also found localized in the mitochondrial inter-membrane space (Kira et al., 2002), nuclei, lysosomes,

production and tyrosine residue nitration, but also

formation, lipid peroxidation, and recruitment

characteristics and functions of SOD, GPx, and catalase.

**5.1. Manganese-dependent superoxide dismutase**

Selenium (Se)-containing GPx is a selenocysteine-containing enzyme, of which multiple isoforms have been identified, including GPx-1, GPx-2, GPx-3, GPx-4, GPx-5, and GPx-6. GPx-1 is a major isoform localized in the cytoplasm and mitochondrial matrix (Orrenius et al., 2007) that metabolized H2O2 to O2 and H2O. However, GPx-1 levels in mitochondria are very low, compared with those in the cytoplasma. GPx-4 is membrane-associated that is found in the inter-membrane space of mitochondria, and is capable of reducing lipid hydroperoxides, alkyl peroxides, and fatty acid hydroperoxides with protect mitochondrial ATP generation. GPx-4 has also been shown to repair mitochondrial oxidative damage (Liang et al., 2009).

Se deficiency is associated with marked decreases in GPx activity and expression and the inhibition of ATP production. Patients with low GPx activity, have significant associations with increased levels of MDA, viral infection, and retroviral therapy (Stephensen et al., 2007). GPx can interfere with nuclear factor-kB (NF-kB) activation by IL-1 and TNF-a, inhibit cyclooxygenase-2 (COX-2) expression along with reduce production of arachidonic acid (AA) metabolites, prevent transport of lipid peroxides and oxidative damage, and maintain the mitochondrial oxidative-phosphorylation (Brigelius-Flohé, 2006; Cole-Ezea et al., 2012). Further, lipoproteins synthesis and secretions have been shown to decline by lipid peroxides (Murthy et al., 1998), indicating that activated GPx can attenuate hepatic triglyceride accumulation.

### **5.4. Catalase**

Catalase is also an important antioxidant enzyme that catalyzes the conversion of H2O2 to H2O. Catalase consists of four subunits, each of which contains a ferric (Fe+3) heme group bound to its active site (Bras et al., 2005); however, Fe deficiency causes a significant decrease of catalase activity. The mitochondrial membrane is impermeable to catalase. Catalase is found primarily in peroxisomes and is also present in heart mitochondria (Bai and Cederbaum, 2001), but has not been found in mitochondria from other tissues (Phung et al., 1994). In fact, in the presence of large amounts of H2O2 and thereby diffusing to the cytosol from the mitochondria, catalase along with GPx becomes the most important scavenger in the cytosol. Various studies have reported lower plasma and erythrocyte catalase activity and increased oxidative stress in patients suffering from mitochondriarelated diseases (Wang et al., 2005; Tinahones et al., 2009; Guo et al., 2011).

Mitochondrial Free Radicals, Antioxidants, Nutrient Substances, and Chronic Hepatitis C 245

fibrogenesis (Fromenty et al., 2004; Rolo et al., 2012). HCV core proteins induced ROS generation leads to a decreased hepcidin expression also contribute to Fe accumulation (Nagashima et al., 2006). Fe overload induced hepatic 8-oxo-dG and eventually increased mitochondrial injury and the risk of hepatocellular carcinoma development (Furutani et al., 2006; Moriya et al., 2010). Thus, increased oxidative stress and altered mitochondrial function both in vitro and in vivo is proven to be involved in chronic hepatitis C infection

Chronic HCV-infected patients were observed to have an increase or decrease in plasma and erythrocyte SOD and GPx activity, higher, lower, or unchanged catalase levels (Ko et al., 2005b; Kaya et al., 2006; Levent et al., 2006), increased serum and plasma Fe, and decreases in serum, plasma, and erythrocyte Zn and Se concentrations (Czuczejko et al., 2003; Ko et al., 2005b; Himoto et al., 2011; Khan et al., 2012). Associations have been observed between plasma MDA, SOD, and GPx levels with viral loads (Ko et al., 2005b). There were significant negative relationships between MDA and HCV-RNA levels with Zn contents in erythrocytes and whole blood. Se deficiency has been observed to be inversely associated with HCV-RNA loads, the severity of hepatic fibrosis, and IR in HCV-infected patients (Ko et al., 2005b; Himoto et al., 2011; Chen et al., 2012). On the other hand, serum, plasma, and erythrocyte levels of Fe and Cu were significantly higher in hepatitis C patients. Positive correlations were also noted between plasma Cu and hepatic Fe levels with HCV-RNA in

The evidence regarding antioxidants, some nutrients along with substances play an important role in mitochondrial resuscitation (Liu and Ames, 2005). GSH and vitamin B complex (B1, B2, B3, B6, pantothenic acid, biotin, and folic acid) protect mitochondria from oxidative damage, improve mitochondrial function, act as cofactors or substrates to protect mitochondrial enzymes, and restore GSH content. Further, these components can enter cells and mitochondria following exogenous treatment (Liu et al., 2009). Deficiency in vitamin B complex and GSH leads to decreased mitochondrial membrane potential, decreased ATP synthesis, and increased oxidative stress and inflammatory responses

Patients with chronic HCV infection have significantly lowered plasma vitamin B1, B2, B6, C, and folic acid levels. Anti-HCV therapy causes further decrease in vitamin B1, B2, B6 and E concentrations and reduces SOD and GPx activity (Lin and Yin, 2009). These patients were also observed to have significantly higher plasma homocysteine (a sulfur-containing amino acid, which is influence by vitamin B2, 6, 12, and folic acid) concentrations and lower concentrations of folic acid and vitamin B12 (Roca et al., 2012). The plasma homocysteine levels were inversely correlated with the concentrations of folic acid in HCV-infected patients (our unpublished observation). SVR patients have been observed to have lower

and is thought to contribute to its progression.

**6.1. Alterations in enzymatic antioxidants and cofactors**

these patients (Fargion et al., 1997; Ko et al., 2005b; Guo et al., 2012).

**6.2. Inadequate vitamins and glutathione status**

(Depeint et al., 2006).

### **6. Mitochondrial injury in chronic Hepatitis C**

Aberrant production of mitochondrial ROS and decrease GSH is though to be caused by HCV core proteins and possibly contributes to oxidative stress in HCV-infected patients (Thorén et al., 2004; Choi and Ou, 2006; Simula and de Re, 2010). Decreased mtDNA levels have also been found in these patients (Barbaro et al., 1999; Bäuerle et al., 2005).

In infectious cell system, MPTP was shown to prevent a range of pathological changes included by HCV core proteins, including the following: induction of ROS, reduction of respiration, disruption of mitochondrial membrane potential, increased mitochondrial permeability transition in response to exogenous oxidants and TNF-a, loss of complex I activity, cleavage of DNA repair enzyme poly (ADP-ribose) polymerase, overproduction of mitochondrial ROS and 8-oxo-dG, Ca+2 overload, decreased GSH, incorporation of core proteins into the mitochondrial outer membranes and endoplasmic reticulum via its COOHterminal region, and enhanced release of cytochrome c from the mitochondrial to the cytosolic fraction (Okuda et al., 2002; Korenaga et al., 2005a, b; Hara et al., 2006; Piccoli et al., 2007; Quarato et al., 2012). On the other hand, HCV core protein has been shown to induced IR (Cheng et al., 2005). HCV-induced ROS generation suppresses the expression of hepcidin (i.e., a peptide which regulate Fe metabolism by decreasing Fe absorption), facilitating the Fe overload; whereas hepcidin expression was restored by antioxidants (Miura et al., 2008). Fe overload in vitro were observed to cause further ROS augmentation and amplify the expression of catalase, Cu,Zn-SOD, and NADPH dehydrogenase (Moriya et al., 2010). These observations presented that increased intracellular Fe and oxidative stress, in turn, aggravates HCV-induced mitochondrial damage.

In animal models of HCV infection, increased ROS, decreased GSH and NADPH levels in liver mitochondria, and increased intrahepatic lipid peroxidation in response to CCl4 have been observed (Okuda et al., 2002; Korenaga et al., 2005a, b). Further, altered mitochondrial function has shown that not only results in hepatic fat accumulation but also leads to increased ROS that induces inflammatory response, thereby activating stellate cells and fibrogenesis (Fromenty et al., 2004; Rolo et al., 2012). HCV core proteins induced ROS generation leads to a decreased hepcidin expression also contribute to Fe accumulation (Nagashima et al., 2006). Fe overload induced hepatic 8-oxo-dG and eventually increased mitochondrial injury and the risk of hepatocellular carcinoma development (Furutani et al., 2006; Moriya et al., 2010). Thus, increased oxidative stress and altered mitochondrial function both in vitro and in vivo is proven to be involved in chronic hepatitis C infection and is thought to contribute to its progression.

### **6.1. Alterations in enzymatic antioxidants and cofactors**

244 Antioxidant Enzyme

**5.4. Catalase**

Catalase is also an important antioxidant enzyme that catalyzes the conversion of H2O2 to H2O. Catalase consists of four subunits, each of which contains a ferric (Fe+3) heme group bound to its active site (Bras et al., 2005); however, Fe deficiency causes a significant decrease of catalase activity. The mitochondrial membrane is impermeable to catalase. Catalase is found primarily in peroxisomes and is also present in heart mitochondria (Bai and Cederbaum, 2001), but has not been found in mitochondria from other tissues (Phung et al., 1994). In fact, in the presence of large amounts of H2O2 and thereby diffusing to the cytosol from the mitochondria, catalase along with GPx becomes the most important scavenger in the cytosol. Various studies have reported lower plasma and erythrocyte catalase activity and increased oxidative stress in patients suffering from mitochondria-

Aberrant production of mitochondrial ROS and decrease GSH is though to be caused by HCV core proteins and possibly contributes to oxidative stress in HCV-infected patients (Thorén et al., 2004; Choi and Ou, 2006; Simula and de Re, 2010). Decreased mtDNA levels

In infectious cell system, MPTP was shown to prevent a range of pathological changes included by HCV core proteins, including the following: induction of ROS, reduction of respiration, disruption of mitochondrial membrane potential, increased mitochondrial permeability transition in response to exogenous oxidants and TNF-a, loss of complex I activity, cleavage of DNA repair enzyme poly (ADP-ribose) polymerase, overproduction of mitochondrial ROS and 8-oxo-dG, Ca+2 overload, decreased GSH, incorporation of core proteins into the mitochondrial outer membranes and endoplasmic reticulum via its COOHterminal region, and enhanced release of cytochrome c from the mitochondrial to the cytosolic fraction (Okuda et al., 2002; Korenaga et al., 2005a, b; Hara et al., 2006; Piccoli et al., 2007; Quarato et al., 2012). On the other hand, HCV core protein has been shown to induced IR (Cheng et al., 2005). HCV-induced ROS generation suppresses the expression of hepcidin (i.e., a peptide which regulate Fe metabolism by decreasing Fe absorption), facilitating the Fe overload; whereas hepcidin expression was restored by antioxidants (Miura et al., 2008). Fe overload in vitro were observed to cause further ROS augmentation and amplify the expression of catalase, Cu,Zn-SOD, and NADPH dehydrogenase (Moriya et al., 2010). These observations presented that increased intracellular Fe and oxidative stress, in turn,

In animal models of HCV infection, increased ROS, decreased GSH and NADPH levels in liver mitochondria, and increased intrahepatic lipid peroxidation in response to CCl4 have been observed (Okuda et al., 2002; Korenaga et al., 2005a, b). Further, altered mitochondrial function has shown that not only results in hepatic fat accumulation but also leads to increased ROS that induces inflammatory response, thereby activating stellate cells and

related diseases (Wang et al., 2005; Tinahones et al., 2009; Guo et al., 2011).

have also been found in these patients (Barbaro et al., 1999; Bäuerle et al., 2005).

**6. Mitochondrial injury in chronic Hepatitis C**

aggravates HCV-induced mitochondrial damage.

Chronic HCV-infected patients were observed to have an increase or decrease in plasma and erythrocyte SOD and GPx activity, higher, lower, or unchanged catalase levels (Ko et al., 2005b; Kaya et al., 2006; Levent et al., 2006), increased serum and plasma Fe, and decreases in serum, plasma, and erythrocyte Zn and Se concentrations (Czuczejko et al., 2003; Ko et al., 2005b; Himoto et al., 2011; Khan et al., 2012). Associations have been observed between plasma MDA, SOD, and GPx levels with viral loads (Ko et al., 2005b). There were significant negative relationships between MDA and HCV-RNA levels with Zn contents in erythrocytes and whole blood. Se deficiency has been observed to be inversely associated with HCV-RNA loads, the severity of hepatic fibrosis, and IR in HCV-infected patients (Ko et al., 2005b; Himoto et al., 2011; Chen et al., 2012). On the other hand, serum, plasma, and erythrocyte levels of Fe and Cu were significantly higher in hepatitis C patients. Positive correlations were also noted between plasma Cu and hepatic Fe levels with HCV-RNA in these patients (Fargion et al., 1997; Ko et al., 2005b; Guo et al., 2012).

### **6.2. Inadequate vitamins and glutathione status**

The evidence regarding antioxidants, some nutrients along with substances play an important role in mitochondrial resuscitation (Liu and Ames, 2005). GSH and vitamin B complex (B1, B2, B3, B6, pantothenic acid, biotin, and folic acid) protect mitochondria from oxidative damage, improve mitochondrial function, act as cofactors or substrates to protect mitochondrial enzymes, and restore GSH content. Further, these components can enter cells and mitochondria following exogenous treatment (Liu et al., 2009). Deficiency in vitamin B complex and GSH leads to decreased mitochondrial membrane potential, decreased ATP synthesis, and increased oxidative stress and inflammatory responses (Depeint et al., 2006).

Patients with chronic HCV infection have significantly lowered plasma vitamin B1, B2, B6, C, and folic acid levels. Anti-HCV therapy causes further decrease in vitamin B1, B2, B6 and E concentrations and reduces SOD and GPx activity (Lin and Yin, 2009). These patients were also observed to have significantly higher plasma homocysteine (a sulfur-containing amino acid, which is influence by vitamin B2, 6, 12, and folic acid) concentrations and lower concentrations of folic acid and vitamin B12 (Roca et al., 2012). The plasma homocysteine levels were inversely correlated with the concentrations of folic acid in HCV-infected patients (our unpublished observation). SVR patients have been observed to have lower

plasma homocysteine levels than non-SVR patients (Borgia et al., 2009). Pre-treatment with IFN-a and ribavirin in chronic HCV-infected patients, serum vitamin B12 levels are positively correlated to end-of-treatment response (Rosenberg and Hagen, 2011).

Mitochondrial Free Radicals, Antioxidants, Nutrient Substances, and Chronic Hepatitis C 247

In clinical observation, the daily dose of polaprezinc includes 34 mg elemental Zn for six months that markedly decreases both ALT and aspartate aminotransferase (AST) levels and enhances the response to IFN-a therapy (Takagi et al., 2001; Nagamine et al., 2000; Matsuoka et al., 2009). However, Zn administration did not affect virologic response (Takagi et al., 2001), SVR, and adverse side effects except for gastrointestinal disturbance (Suzuki et al., 2006). On the other hand, Zn responders were observed to have a clearly lower cumulative incidence of hepatocellular carcinoma in patients suffering from chronic HCV infection and liver cirrhosis. For those Zn non-responders, suggesting a higher daily Zn dose may be needed to increase the response to IFN-a treatment (Matsuoka et al., 2009). Polaprezinc was administrated at 51 mg elemental Zn per day for six months to hepatitis C patients, the rate of reduction of ALT levels was observed to positively correlate with that of ferritin (i.e., a clinical marker of iron storage protein, inflammation and oxidative stress), whereas Zn

These observations suggest that Zn supplementation in HCV-infected patients may improve nutritional status, and thereby decrease inflammation and liver enzyme levels. Administration of Zn supplement has shown to reduce potential oxidative stress and

Vitamin C is an essential and water-soluble antioxidant molecule efficiently protects

as a cofactor for enzymes involved in synthesis of collagen or carnitine (essential for the transport of fatty acids into mitochondria), and the mitochondrial reduction of vitamin E, ferricytochrome c, lipoic acid, and GSH (Sagun et al., 2005; Levine et al., 2011). In vivo study has shown that administration of vitamin C supplementation markedly increases plasma, leukocyte, and mitochondrial vitamin C concentrations and mitochondria themselves can produce vitamin C (May et al., 2007). Vitamin C supplementation is observed to significantly enhance NK cells activity, monocytes, T- and B-lymphocytes, and increase the Th1/Th2 ratio, balancing the immune function (Heuser and Vojdani, 1997; Chang et al., 2009). Deficiency in vitamin C can cause oxidative stress and lead to decreased immune response, impaired membrane integrity, and altered membrane fluidity (Maggini et al., 2007). On the other hand, vitamin E (a-tocopherol) is a fat-soluble antioxidant that prevents lipid peroxidation and scavenges lipid peroxyl radicals. Vitamin E administered in the diet predominantly localizes in the mitochondrial inner- and outer-membranes (Lauridsen and Jensen, 2012). Effects of vitamin E were also observed which involving in heme biosynthesis, immune system modulation, Se-containing proteins formation, and the integrity of

Studies in an animal model demonstrates that combined administration of vitamin E and C, markedly decreases the carbonyl group content in mitochondrial proteins and enhances SOD and citrate synthase activity (Rosa et al., 2009). On the other hand, clinical observation has been shown to have significantly lower plasma concentrations of a-tocopherol, ascorbic

and O2**\*-**. Vitamin C severs

administration did not affect virologic response (Himoto et al., 2007).

stabilize erythrocyte membrane, but not to inhibit virus.

mitochondrial membranes (Mabalirajan et al., 2009).

biological materials against damaging free radicals such as OH**\***

**7.2. Vitamin C and E supplementation**

Besides the above-noted findings, HCV-infected patients have lower GSH and higher GSSG concentrations in blood, plasma, liver, and the lymphatic system. However, the ratio of GSSG to GSH increases, indicating a high GSH turnover and oxidative stress (Seronello et al., 2007; Lin and Yin, 2009). Thus, GSH depletion might be one reason for the low rate of patient response to treatment (Bernhard et al., 1998). Taken together, these observations suggest that the antioxidant defense is clearly depleted in patients suffering from hepatitis C.

### **7. Effects of antioxidants and nutrient substances in Hepatitis C**

The supplementation of antioxidants or cofactors may show greater benefits in mitochondrial function and antiviral therapy in patients infected with HCV. Recently, the combination of antioxidant with antiviral therapy is recommended for hepatitis C.

### **7.1. Zn supplementation**

Zn as a cofactor of Cu,Zn-SOD and thus is a potential modulator of mitochondrial oxidative phosphorylation. Decreased serum and plasma Zn may serve as a potential inflammatory marker, similar to CRP, but it may also reduce hepatic inflammation in chronic hepatitis C patients through induction of Zn metallothionein, which functions as a free radical scavenger and immune-modulator (Ko et al., 2005a; Guo et al., 2012). Zn has been shown to influence antigen-specific immune response and unspecific immune mechanisms (Grüngreiff and Reinhold, 2010). Disturbances in Zn homeostasis can lead to a shift in the Th1/Th2 balance towards a Th2 response (Rink and Haase, 2007; Prasad, 2009). HCV replication enhances activation of the NF-kB-signal pathway triggered by TNF-a (Kanda et al., 2006); however, Zn inhibits NF-kB activation results in decreasing inflammatory cytokine levels (Prasad, 2008). The non-structural protein NS5A is an active component of HCV replicase and is a Zn metalloprotein, suggesting complex interaction between Zn and NS5A activation (Tellinghuisen et al., 2004). In addition, some of the adverse side effects seen during antiviral treatment were similar to the symptoms of Zn deficiency (Saper and Rash, 2009). The effects of Zn administration on these side effects, oxidative stress, and inflammatory responses remain to be determined.

The concentrations of serum Zn were declined further in hepatitis C patients receiving treatment with IFN-a and ribavirin; whereas Zn concentrations were remediable by daily administration of 50 mg elemental Zn from Zn gluconate for six months. Serum Zn level was also found to be significantly higher in complete responders to IFN-a therapy than in non-responders. No apparent difference was seen in virologic response, but adverse side effects including gastrointestinal disturbance, weight loss, and mild anemia were significantly decreased (Ko et al., 2005a).

In clinical observation, the daily dose of polaprezinc includes 34 mg elemental Zn for six months that markedly decreases both ALT and aspartate aminotransferase (AST) levels and enhances the response to IFN-a therapy (Takagi et al., 2001; Nagamine et al., 2000; Matsuoka et al., 2009). However, Zn administration did not affect virologic response (Takagi et al., 2001), SVR, and adverse side effects except for gastrointestinal disturbance (Suzuki et al., 2006). On the other hand, Zn responders were observed to have a clearly lower cumulative incidence of hepatocellular carcinoma in patients suffering from chronic HCV infection and liver cirrhosis. For those Zn non-responders, suggesting a higher daily Zn dose may be needed to increase the response to IFN-a treatment (Matsuoka et al., 2009). Polaprezinc was administrated at 51 mg elemental Zn per day for six months to hepatitis C patients, the rate of reduction of ALT levels was observed to positively correlate with that of ferritin (i.e., a clinical marker of iron storage protein, inflammation and oxidative stress), whereas Zn administration did not affect virologic response (Himoto et al., 2007).

These observations suggest that Zn supplementation in HCV-infected patients may improve nutritional status, and thereby decrease inflammation and liver enzyme levels. Administration of Zn supplement has shown to reduce potential oxidative stress and stabilize erythrocyte membrane, but not to inhibit virus.

### **7.2. Vitamin C and E supplementation**

246 Antioxidant Enzyme

C.

**7.1. Zn supplementation**

inflammatory responses remain to be determined.

significantly decreased (Ko et al., 2005a).

plasma homocysteine levels than non-SVR patients (Borgia et al., 2009). Pre-treatment with IFN-a and ribavirin in chronic HCV-infected patients, serum vitamin B12 levels are

Besides the above-noted findings, HCV-infected patients have lower GSH and higher GSSG concentrations in blood, plasma, liver, and the lymphatic system. However, the ratio of GSSG to GSH increases, indicating a high GSH turnover and oxidative stress (Seronello et al., 2007; Lin and Yin, 2009). Thus, GSH depletion might be one reason for the low rate of patient response to treatment (Bernhard et al., 1998). Taken together, these observations suggest that the antioxidant defense is clearly depleted in patients suffering from hepatitis

The supplementation of antioxidants or cofactors may show greater benefits in mitochondrial function and antiviral therapy in patients infected with HCV. Recently, the

Zn as a cofactor of Cu,Zn-SOD and thus is a potential modulator of mitochondrial oxidative phosphorylation. Decreased serum and plasma Zn may serve as a potential inflammatory marker, similar to CRP, but it may also reduce hepatic inflammation in chronic hepatitis C patients through induction of Zn metallothionein, which functions as a free radical scavenger and immune-modulator (Ko et al., 2005a; Guo et al., 2012). Zn has been shown to influence antigen-specific immune response and unspecific immune mechanisms (Grüngreiff and Reinhold, 2010). Disturbances in Zn homeostasis can lead to a shift in the Th1/Th2 balance towards a Th2 response (Rink and Haase, 2007; Prasad, 2009). HCV replication enhances activation of the NF-kB-signal pathway triggered by TNF-a (Kanda et al., 2006); however, Zn inhibits NF-kB activation results in decreasing inflammatory cytokine levels (Prasad, 2008). The non-structural protein NS5A is an active component of HCV replicase and is a Zn metalloprotein, suggesting complex interaction between Zn and NS5A activation (Tellinghuisen et al., 2004). In addition, some of the adverse side effects seen during antiviral treatment were similar to the symptoms of Zn deficiency (Saper and Rash, 2009). The effects of Zn administration on these side effects, oxidative stress, and

The concentrations of serum Zn were declined further in hepatitis C patients receiving treatment with IFN-a and ribavirin; whereas Zn concentrations were remediable by daily administration of 50 mg elemental Zn from Zn gluconate for six months. Serum Zn level was also found to be significantly higher in complete responders to IFN-a therapy than in non-responders. No apparent difference was seen in virologic response, but adverse side effects including gastrointestinal disturbance, weight loss, and mild anemia were

positively correlated to end-of-treatment response (Rosenberg and Hagen, 2011).

**7. Effects of antioxidants and nutrient substances in Hepatitis C**

combination of antioxidant with antiviral therapy is recommended for hepatitis C.

Vitamin C is an essential and water-soluble antioxidant molecule efficiently protects biological materials against damaging free radicals such as OH**\*** and O2**\*-**. Vitamin C severs as a cofactor for enzymes involved in synthesis of collagen or carnitine (essential for the transport of fatty acids into mitochondria), and the mitochondrial reduction of vitamin E, ferricytochrome c, lipoic acid, and GSH (Sagun et al., 2005; Levine et al., 2011). In vivo study has shown that administration of vitamin C supplementation markedly increases plasma, leukocyte, and mitochondrial vitamin C concentrations and mitochondria themselves can produce vitamin C (May et al., 2007). Vitamin C supplementation is observed to significantly enhance NK cells activity, monocytes, T- and B-lymphocytes, and increase the Th1/Th2 ratio, balancing the immune function (Heuser and Vojdani, 1997; Chang et al., 2009). Deficiency in vitamin C can cause oxidative stress and lead to decreased immune response, impaired membrane integrity, and altered membrane fluidity (Maggini et al., 2007). On the other hand, vitamin E (a-tocopherol) is a fat-soluble antioxidant that prevents lipid peroxidation and scavenges lipid peroxyl radicals. Vitamin E administered in the diet predominantly localizes in the mitochondrial inner- and outer-membranes (Lauridsen and Jensen, 2012). Effects of vitamin E were also observed which involving in heme biosynthesis, immune system modulation, Se-containing proteins formation, and the integrity of mitochondrial membranes (Mabalirajan et al., 2009).

Studies in an animal model demonstrates that combined administration of vitamin E and C, markedly decreases the carbonyl group content in mitochondrial proteins and enhances SOD and citrate synthase activity (Rosa et al., 2009). On the other hand, clinical observation has been shown to have significantly lower plasma concentrations of a-tocopherol, ascorbic acid, and GSH in HCV- infected patients (Lin and Yin, 2009). Plasma a-tocopherol or ascorbic acid levels were negatively correlated with F2-isoprostane and ALT levels (our unpublished results). Thus, further studies will be needed to clarify the effect of a combination of vitamin C and vitamin E on chronic hepatitis C patients treated with IFN-a and ribavirin.

Mitochondrial Free Radicals, Antioxidants, Nutrient Substances, and Chronic Hepatitis C 249

has been observed to significantly decrease plasma MDA, HCV-RNA load, and prevent the decrease in polyunsaturated fatty acids of erythrocyte membrane phospholipids in patients during IFN-a plus ribavirin therapy with vitamin E (300 mg a-tocopherol acetate/day) and vitamin C (600 mg ascorbic acid/day) supplementation (Murakami et al., 2007). Results from clinical studies suggest that Zn supplementation is more effective against HCV when given

Se also plays a vital role in the redox regulation and antioxidant function and immunomodulatory effects. These effects are potentiated by the presence of vitamin E. Se deficiency was observed to have reduced T-lymphocytes, impaired lymphocyte proliferation and function, and altered innate immunity (NK cells, dendritic cells, and neutrophils)(Maggini et al., 2007; Hoffmann and Berry, 2008). On the other hand, decreased Se levels and Sedependent GPx activity either in plasma or in erythrocytes suggests that the anti-oxidative capability is limited in patients with chronic HCV infection (Ko et al., 2005b; Guo et al., 2012). Significantly higher viral loads correlate with decreased blood Se and GPx activity in HCV-infected patients (Ko et al., 2005b; Himoto et al., 2011; Khan et al., 2012). Associations have been observed between plasma MDA, protein carbonyl group, and ALT levels with plasma Se concentrations (our unpublished results). Serum and plasma Se levels significantly decrease in proportion to the severity of hepatic fibrosis, IR, and HCV-RNA levels, and correlate positively with plasma, erythrocyte GPx activity and Zn concentrations. Also, increased IR is associated with higher HCV-RNA levels (Ko et al., 2005b; Himoto et al.,

Se-dependent GPx modules encoded in RNA viruses have been found (Zhang et al., 1999). HCV- infected patients with early virological response (EVR), which is defined as undetectable HCV-RNA or a less than two log drop in HCV-RNA at week 12, have significantly higher plasma Se concentrations and GPx activity compared to those with non-EVR patients. A similar difference between SVR and non-SVR patients has been observed (C-H Guo, W-S Ko, and P-C Chen; unpublished results). Thus, Se status might be a sensitive

HCV-infected patients who received antioxidant supplementation (633 mg atocopherol/day, 500 mg ascorbic acid/day, and 200 mg Se/day for six months) had significantly higher plasma levels of ascorbic acid and a-tocopherol and higher erythrocyte GPx activity. However, the supplementation had no effects on ALT, viral load or oxidative

This finding is difficult to interpret because the potential synergy between vitamin E and Se is well documented. On the basis of the finding, these results might be attributed to viral genotypes or a much high viral load. Based on our previous experience with clinical trials, this dosage may not be enough to be therapeutic for Se therapy, even though the recommended dietary allowances of Se in the USA are 55-70 mg/day for adults.

indicator for the sustained response to therapy in chronic hepatitis C patients.

along with antioxidants (combinations of vitamin C and vitamin E).

**7.4. Vitamin C, E, and Se supplementation**

2011).

markers (Groenbaek et al., 2006).

Administration of vitamin E (804 mg a-tocopherol/day) for eight weeks has been shown to decrease protein carbonyl group levels; whereas did not significantly affect ALT levels, virologic response, and fibrosis process in HCV-infected patients (Houglum et al., 1997). Further studies indicate that plasma and erythrocyte a-tocopherol and plasma ascorbic acid levels increased, and serum levels of ALT decreased significantly after two weeks of treatment with Vitamin E (500 mg a-tocopherol/day) and C (750 mg ascorbic acid/day) supplementation (Murakami et al., 2006). The combined administration of vitamin E (1342 mg a-tocopherol/day) with vitamin C (100 mg ascorbic acid/day) for 48 weeks has been shown to decreases in ribavirin-induced anemia but not SVR in patients with HCV infection (Kawaguchi et al., 2007). Patients undergoing IFN-a and ribavirin treatment have markedly higher AA and decreased EPA levels in PBMC. The combined administration of vitamin E with vitamin C for four weeks prevents the decrease in PBMC EPA and the increase in the ratio of AA to EPA in these patients (Murakami et al., 2006). Eight weeks of such treatment led to increases in hemoglobin levels and significantly elevated erythrocyte EPA concentrations in these patients (Hino et al., 2006).

Studies have demonstrated that ribavirin's toxicity decrease intracellular energy metabolism, increase oxidative membrane damage, and accelerate hemolytic anemia in the combined therapy of IFN-a and ribavirin (Assem and Yousri, 2011). Ribavirin-induced ROS would increase EPA peroxidation and result in alteration in fatty acid compositions of erythrocyte membranes. A combination antioxidant treatment improves the antioxidant capacity than vitamin E alone in HCV-infected patients, thereby protecting erythrocyte EPA depletion. Based on our previous experience with clinical trials, the dosages of vitamin C can range from 1000 mg to 6000 mg. These patients who take greater amount of vitamin C, which can offers greater benefit in raising GSH concentrations. Additionally, a combination of vitamin C and other antioxidants may further increase the efficiency of antiviral therapy.

### **7.3. Vitamin C, E, and Zn supplementation**

There is a need for effective antiviral treatments that decrease the inflammation and increase antiviral response. The availability of such treatments would maintain erythrocyte integrity and resistance to hemolysis. It seems reasonable that co-administration of Zn and antioxidants may be more effective in antiviral therapy.

HCV-infected patients receiving antioxidant supplementation (combination of 800 mg atocopherol/day, 500 mg ascorbic acid/day and 40 mg Zn/day for six months) showed significant improvement in antioxidant enzyme activity and ALT reduction (Farias et al., 2012). Polaprezinc supplementation (equivalent to 34 mg elemental Zn) daily for 12 months has been observed to significantly decrease plasma MDA, HCV-RNA load, and prevent the decrease in polyunsaturated fatty acids of erythrocyte membrane phospholipids in patients during IFN-a plus ribavirin therapy with vitamin E (300 mg a-tocopherol acetate/day) and vitamin C (600 mg ascorbic acid/day) supplementation (Murakami et al., 2007). Results from clinical studies suggest that Zn supplementation is more effective against HCV when given along with antioxidants (combinations of vitamin C and vitamin E).

### **7.4. Vitamin C, E, and Se supplementation**

248 Antioxidant Enzyme

and ribavirin.

concentrations in these patients (Hino et al., 2006).

**7.3. Vitamin C, E, and Zn supplementation**

antioxidants may be more effective in antiviral therapy.

acid, and GSH in HCV- infected patients (Lin and Yin, 2009). Plasma a-tocopherol or ascorbic acid levels were negatively correlated with F2-isoprostane and ALT levels (our unpublished results). Thus, further studies will be needed to clarify the effect of a combination of vitamin C and vitamin E on chronic hepatitis C patients treated with IFN-a

Administration of vitamin E (804 mg a-tocopherol/day) for eight weeks has been shown to decrease protein carbonyl group levels; whereas did not significantly affect ALT levels, virologic response, and fibrosis process in HCV-infected patients (Houglum et al., 1997). Further studies indicate that plasma and erythrocyte a-tocopherol and plasma ascorbic acid levels increased, and serum levels of ALT decreased significantly after two weeks of treatment with Vitamin E (500 mg a-tocopherol/day) and C (750 mg ascorbic acid/day) supplementation (Murakami et al., 2006). The combined administration of vitamin E (1342 mg a-tocopherol/day) with vitamin C (100 mg ascorbic acid/day) for 48 weeks has been shown to decreases in ribavirin-induced anemia but not SVR in patients with HCV infection (Kawaguchi et al., 2007). Patients undergoing IFN-a and ribavirin treatment have markedly higher AA and decreased EPA levels in PBMC. The combined administration of vitamin E with vitamin C for four weeks prevents the decrease in PBMC EPA and the increase in the ratio of AA to EPA in these patients (Murakami et al., 2006). Eight weeks of such treatment led to increases in hemoglobin levels and significantly elevated erythrocyte EPA

Studies have demonstrated that ribavirin's toxicity decrease intracellular energy metabolism, increase oxidative membrane damage, and accelerate hemolytic anemia in the combined therapy of IFN-a and ribavirin (Assem and Yousri, 2011). Ribavirin-induced ROS would increase EPA peroxidation and result in alteration in fatty acid compositions of erythrocyte membranes. A combination antioxidant treatment improves the antioxidant capacity than vitamin E alone in HCV-infected patients, thereby protecting erythrocyte EPA depletion. Based on our previous experience with clinical trials, the dosages of vitamin C can range from 1000 mg to 6000 mg. These patients who take greater amount of vitamin C, which can offers greater benefit in raising GSH concentrations. Additionally, a combination of vitamin C and other antioxidants may further increase the efficiency of antiviral therapy.

There is a need for effective antiviral treatments that decrease the inflammation and increase antiviral response. The availability of such treatments would maintain erythrocyte integrity and resistance to hemolysis. It seems reasonable that co-administration of Zn and

HCV-infected patients receiving antioxidant supplementation (combination of 800 mg atocopherol/day, 500 mg ascorbic acid/day and 40 mg Zn/day for six months) showed significant improvement in antioxidant enzyme activity and ALT reduction (Farias et al., 2012). Polaprezinc supplementation (equivalent to 34 mg elemental Zn) daily for 12 months Se also plays a vital role in the redox regulation and antioxidant function and immunomodulatory effects. These effects are potentiated by the presence of vitamin E. Se deficiency was observed to have reduced T-lymphocytes, impaired lymphocyte proliferation and function, and altered innate immunity (NK cells, dendritic cells, and neutrophils)(Maggini et al., 2007; Hoffmann and Berry, 2008). On the other hand, decreased Se levels and Sedependent GPx activity either in plasma or in erythrocytes suggests that the anti-oxidative capability is limited in patients with chronic HCV infection (Ko et al., 2005b; Guo et al., 2012). Significantly higher viral loads correlate with decreased blood Se and GPx activity in HCV-infected patients (Ko et al., 2005b; Himoto et al., 2011; Khan et al., 2012). Associations have been observed between plasma MDA, protein carbonyl group, and ALT levels with plasma Se concentrations (our unpublished results). Serum and plasma Se levels significantly decrease in proportion to the severity of hepatic fibrosis, IR, and HCV-RNA levels, and correlate positively with plasma, erythrocyte GPx activity and Zn concentrations. Also, increased IR is associated with higher HCV-RNA levels (Ko et al., 2005b; Himoto et al., 2011).

Se-dependent GPx modules encoded in RNA viruses have been found (Zhang et al., 1999). HCV- infected patients with early virological response (EVR), which is defined as undetectable HCV-RNA or a less than two log drop in HCV-RNA at week 12, have significantly higher plasma Se concentrations and GPx activity compared to those with non-EVR patients. A similar difference between SVR and non-SVR patients has been observed (C-H Guo, W-S Ko, and P-C Chen; unpublished results). Thus, Se status might be a sensitive indicator for the sustained response to therapy in chronic hepatitis C patients.

HCV-infected patients who received antioxidant supplementation (633 mg atocopherol/day, 500 mg ascorbic acid/day, and 200 mg Se/day for six months) had significantly higher plasma levels of ascorbic acid and a-tocopherol and higher erythrocyte GPx activity. However, the supplementation had no effects on ALT, viral load or oxidative markers (Groenbaek et al., 2006).

This finding is difficult to interpret because the potential synergy between vitamin E and Se is well documented. On the basis of the finding, these results might be attributed to viral genotypes or a much high viral load. Based on our previous experience with clinical trials, this dosage may not be enough to be therapeutic for Se therapy, even though the recommended dietary allowances of Se in the USA are 55-70 mg/day for adults.

Additionally, there is variability in the absorption and therapeutic mechanism of Se that is related to the forms of Se. Further large-scale studies are needed to elucidate the effects of Se alone or in combination in chronic hepatitis C patients treated with IFN-a and ribavirin.

Mitochondrial Free Radicals, Antioxidants, Nutrient Substances, and Chronic Hepatitis C 251

and serum 8-oxo-dG levels after six-months of treatment with IFN-a, ribavirin, and antioxidants (300 mg a-tocopherol/day and 600 mg ascorbic acid/day). EPA supplementation also decreased the ratio of AA to EPA and increased leukocyte levels (Tomioka et al., 2005; Kawashima et al., 2008); suggesting treatment with EPA prevents AA accumulation. Thus, these observations suggest that the combination of EPA and antioxidants (vitamin C and vitamin E) may ameliorate inflammation and oxidative stress

The bioavailability and efficacy of fish oils are frequently controversial, although ethyl ester (EE)- or triglyceride (TG)-form, has recently been introduced into clinical practices. EE-form fish oil has shown some unpredictable side effects in clinical application (Data sources from Dr. P-J. Liu). Both ethanol and methanol, the metabolites of EE-form (catalyzed by carboxy ester hydrolase) that may contribute to the adverse events include gastrointestinal disorder, vomiting, and hypertriglyceridemia. Thus, the choice of fish oils for clinical application will

Beside the use of those antioxidants, some nutrient substances treatments in mitochondrial damage have been reported to produce a positive effect, as reviewed in Tarnopolsky (2008) and Orsucci et al (2009). Further, the combined treatment with antioxidants and other nutrients has been show to efficiently decrease mitochondrial oxidative injury, increase

Beneficial therapeutic responses to CoQ (Gane et al., 2010), carnitine (Romano et al., 2008; Malaguarnera et al., 2011), choline (Niederau et al., 1998), or N-acetyl-cysteine (Cimino et al., 1998; Neri et al., 2000) have been observed in patients with hepatitis C. Furthermore, standard treatment with multiple nutrient supplements (including 2000 mg/day of ascorbic acid, 150 mg/day of GSH, 150 mg/day of LA, 800 IU/day of d-a-tocopherol as well as silymarin, glycyrrhiza, and schizandrae) for six months leads to significant declines in ALT levels, improvements in liver histological status, and decreased HCV-RNA loads. Such supplements also produce mild beneficial effect in the inflammatory response of patients who are non-responders to IFN-a (Melhem et al., 2001; Gabbay et al., 2007). Patients with chronic hepatitis C who received a combination of natural supplements (CoQ, EPA/DHA, Se, and vitamin B complex) for six months demonstrated significant improvements in immune function, reduced adverse side effects, and decreases in HCV-RNA loads. Reductions in the rate of non-responders were also observed (manuscript from Dr. Simon Hsia). These observations suggest that the synergistic effects of antioxidants and

and thereby increase the response of antiviral therapy in HCV-infected patients.

have to be considered, particularly in chronic HCV-infected patients with NAFLD.

mitochondrial ATP production, and to arrest the progression of clinical symptoms.

mitochondria-related nutrient substances may be effective in antiviral therapy.

In conclusion, significant increases in oxidative stress and alterations in mitochondrial function have been observed in patients infected with HCV, as well as in animal and cell

**8. Summary**

**7.6. Combination of antioxidants and nutrient substances**

### **7.5. Vitamin C, E, and eicosapentaeoic acid supplementation**

Two components of fish oil, eicosapentaeoic acid (EPA) and docosahexaenoic acid (DHA), are referred to as omega-3 or n-3 fatty acids. Both EPA and DHA have been shown to exert antioxidant, anti-inflammatory activities (efficiently suppressed NF-kB activation), and reduction of pro- inflammatory lipid mediators (Merzouk et al., 2003; Calder, 2006) and subsequently incorporate into the mitochondrial membranes and maintain the membrane fluidity (Chapkin et al., 2002, 2009). Thus, both EPA and DHA are essential for mitochondrial function, inhibition of HCV-RNA replication (Liu et al., 2010), increases in insulin sensitivity (Ye et al., 2001) and hepatic lipid metabolism (Araya et al., 2004; Al-Gayyar et al., 2011).

Mitochondrial phospholipid composition, particularly in releases of AA and cardiolipin contents are major contributors to trigger MPTP opening. Cardiolipin is composed of four linoleic acid side chains, which is essential for normal mitochondrial respiration; however, substitute such as long chain saturated and monounsaturated fatty acids weaken mitochondrial function (O'Shea et al., 2009). Recent study has shown that increased saturated fatty acids and cholesterol associated with alteration in mitochondrial membrane and cardiolipin oxidation, which are required for HCV replication (Roe et al., 2011). HCVinfected patients have markedly higher AA and decreased EPA levels in PBMC compared to the healthy controls. In addition, IFN-a and ribavirin treatment can further lead to EPA depletion (Murakami et al., 2006). Supplementation with DHA alone or both DHA and EPA significantly delays Ca2+-induced MPTP opening in normal and hypertrophied myocardium (O'Shea et al., 2009; Khairallah et al., 2010). These changes were accompanied by an increase in DHA and EPA level in mitochondrial phospholipids and decreased AA level (Khairallah et al., 2010).

Both EPA and DHA may induce b-oxidation of fatty acid and upregulation of mitochondrial biogenesis (Ruzickova et al., 2004; Flachs et al., 2005). In rat model, EPA treatment lowered plasma triglyceride and increased b-oxidation of fatty acid in hepatic mitochondria and carnitine palmitoyltransferase-1 activity (Madsen et al., 1999). Treatment with EPA and DHA was observed to reduce in plasma and urinary F2-isoprostanes, which was due to immuno-modulatory effects via EPA and DHA (Mori et al., 2003). Above observations suggest that EPA and DHA supplementation have potential beneficial effects in HCVinfected patients with and without NAFLD.

It is proposed that administration of either EPA alone or both DHA and EPA may compensate the loss of EPA by ribavirin induction in erythrocyte membrane. After oral treatment with EPA (1.8 g/day) for 12 weeks, patients were observed to have significantly decreased ALT levels and higher Th1/Th2 ratio. These patients had clearly lower plasma and serum 8-oxo-dG levels after six-months of treatment with IFN-a, ribavirin, and antioxidants (300 mg a-tocopherol/day and 600 mg ascorbic acid/day). EPA supplementation also decreased the ratio of AA to EPA and increased leukocyte levels (Tomioka et al., 2005; Kawashima et al., 2008); suggesting treatment with EPA prevents AA accumulation. Thus, these observations suggest that the combination of EPA and antioxidants (vitamin C and vitamin E) may ameliorate inflammation and oxidative stress and thereby increase the response of antiviral therapy in HCV-infected patients.

The bioavailability and efficacy of fish oils are frequently controversial, although ethyl ester (EE)- or triglyceride (TG)-form, has recently been introduced into clinical practices. EE-form fish oil has shown some unpredictable side effects in clinical application (Data sources from Dr. P-J. Liu). Both ethanol and methanol, the metabolites of EE-form (catalyzed by carboxy ester hydrolase) that may contribute to the adverse events include gastrointestinal disorder, vomiting, and hypertriglyceridemia. Thus, the choice of fish oils for clinical application will have to be considered, particularly in chronic HCV-infected patients with NAFLD.

### **7.6. Combination of antioxidants and nutrient substances**

Beside the use of those antioxidants, some nutrient substances treatments in mitochondrial damage have been reported to produce a positive effect, as reviewed in Tarnopolsky (2008) and Orsucci et al (2009). Further, the combined treatment with antioxidants and other nutrients has been show to efficiently decrease mitochondrial oxidative injury, increase mitochondrial ATP production, and to arrest the progression of clinical symptoms.

Beneficial therapeutic responses to CoQ (Gane et al., 2010), carnitine (Romano et al., 2008; Malaguarnera et al., 2011), choline (Niederau et al., 1998), or N-acetyl-cysteine (Cimino et al., 1998; Neri et al., 2000) have been observed in patients with hepatitis C. Furthermore, standard treatment with multiple nutrient supplements (including 2000 mg/day of ascorbic acid, 150 mg/day of GSH, 150 mg/day of LA, 800 IU/day of d-a-tocopherol as well as silymarin, glycyrrhiza, and schizandrae) for six months leads to significant declines in ALT levels, improvements in liver histological status, and decreased HCV-RNA loads. Such supplements also produce mild beneficial effect in the inflammatory response of patients who are non-responders to IFN-a (Melhem et al., 2001; Gabbay et al., 2007). Patients with chronic hepatitis C who received a combination of natural supplements (CoQ, EPA/DHA, Se, and vitamin B complex) for six months demonstrated significant improvements in immune function, reduced adverse side effects, and decreases in HCV-RNA loads. Reductions in the rate of non-responders were also observed (manuscript from Dr. Simon Hsia). These observations suggest that the synergistic effects of antioxidants and mitochondria-related nutrient substances may be effective in antiviral therapy.

### **8. Summary**

250 Antioxidant Enzyme

Gayyar et al., 2011).

et al., 2010).

infected patients with and without NAFLD.

Additionally, there is variability in the absorption and therapeutic mechanism of Se that is related to the forms of Se. Further large-scale studies are needed to elucidate the effects of Se alone or in combination in chronic hepatitis C patients treated with IFN-a and ribavirin.

Two components of fish oil, eicosapentaeoic acid (EPA) and docosahexaenoic acid (DHA), are referred to as omega-3 or n-3 fatty acids. Both EPA and DHA have been shown to exert antioxidant, anti-inflammatory activities (efficiently suppressed NF-kB activation), and reduction of pro- inflammatory lipid mediators (Merzouk et al., 2003; Calder, 2006) and subsequently incorporate into the mitochondrial membranes and maintain the membrane fluidity (Chapkin et al., 2002, 2009). Thus, both EPA and DHA are essential for mitochondrial function, inhibition of HCV-RNA replication (Liu et al., 2010), increases in insulin sensitivity (Ye et al., 2001) and hepatic lipid metabolism (Araya et al., 2004; Al-

Mitochondrial phospholipid composition, particularly in releases of AA and cardiolipin contents are major contributors to trigger MPTP opening. Cardiolipin is composed of four linoleic acid side chains, which is essential for normal mitochondrial respiration; however, substitute such as long chain saturated and monounsaturated fatty acids weaken mitochondrial function (O'Shea et al., 2009). Recent study has shown that increased saturated fatty acids and cholesterol associated with alteration in mitochondrial membrane and cardiolipin oxidation, which are required for HCV replication (Roe et al., 2011). HCVinfected patients have markedly higher AA and decreased EPA levels in PBMC compared to the healthy controls. In addition, IFN-a and ribavirin treatment can further lead to EPA depletion (Murakami et al., 2006). Supplementation with DHA alone or both DHA and EPA significantly delays Ca2+-induced MPTP opening in normal and hypertrophied myocardium (O'Shea et al., 2009; Khairallah et al., 2010). These changes were accompanied by an increase in DHA and EPA level in mitochondrial phospholipids and decreased AA level (Khairallah

Both EPA and DHA may induce b-oxidation of fatty acid and upregulation of mitochondrial biogenesis (Ruzickova et al., 2004; Flachs et al., 2005). In rat model, EPA treatment lowered plasma triglyceride and increased b-oxidation of fatty acid in hepatic mitochondria and carnitine palmitoyltransferase-1 activity (Madsen et al., 1999). Treatment with EPA and DHA was observed to reduce in plasma and urinary F2-isoprostanes, which was due to immuno-modulatory effects via EPA and DHA (Mori et al., 2003). Above observations suggest that EPA and DHA supplementation have potential beneficial effects in HCV-

It is proposed that administration of either EPA alone or both DHA and EPA may compensate the loss of EPA by ribavirin induction in erythrocyte membrane. After oral treatment with EPA (1.8 g/day) for 12 weeks, patients were observed to have significantly decreased ALT levels and higher Th1/Th2 ratio. These patients had clearly lower plasma

**7.5. Vitamin C, E, and eicosapentaeoic acid supplementation**

In conclusion, significant increases in oxidative stress and alterations in mitochondrial function have been observed in patients infected with HCV, as well as in animal and cell models of HCV. HCV-induced mitochondrial oxidative damage and increased ROS production facilitate HCV replication and contribute to the progression of hepatitis C. Additionally, mitochondrial dysfunction inducted by HCV reduces the b-oxidation of fatty acid and accelerates ROS formation, causing fat accumulation and hepatic lipid peroxidation. Reduced mitochondrial biogenesis also contributes to development of IR. Clinical observations indicate that therapeutic approaches targeting mitochondrial biogenesis that decrease oxidative damage and increase the response to antiviral therapy are clinically beneficial for chronic HCV-infected patients undergoing IFN-a and ribavirin treatment.

Mitochondrial Free Radicals, Antioxidants, Nutrient Substances, and Chronic Hepatitis C 253

Bäuerle J, Laguno M, Mauss S, Mallolas J, Murillas J, Miquel R, et al. Mitochondrial DNA depletion in liver tissue of patients infected with hepatitis C virus: contributing effect of

Beckman JS, Crow JP. Pathological implications of nitric oxide, superoxide and peroxynitrite

Berdanier CD. Role of membrane lipids in metabolic regulation. Nutr Rev 1988;46:145-149. Bernhard MC, Junker E, Hettinger A, Lauterburg BH. Time course of total cysteine, glutathione and homocysteine in plasma of patients with chronic hepatitis C treated with interferon-α with and without supplementation with N-acetylcysteine. J Hepatol

Bhagavan HN, Chopra RK. Coenzyme Q10: Absorption, tissue uptake, metabolism and

Borgia G, Gentile I, Fortunato G, Borrelli F, Borelli S, de Caterina M, et al. Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin

Brigelius-Flohé R. Glutathione peroxidases and redox-regulated transcription factors. Biol

Brown GC, Borutaite V. Nitric oxide, mitochondria, and cell death. IUBMB Life 2001;52:189-

Calder PC. n−3 polyunsaturated fatty acids, inammation, and inammatory diseases. Am J

Cardin R, Saccoccio G, Masutti F, Bellentani S, Farinati F, Tiribelli C. DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an

Chang HH, Chen CS, Lin JY. High dose vitamin C supplementation increases the Th1/Th2 cytokine secretion ratio, but decreases eosinophilic infiltration in bronchoalveolar lavage fluid of ovalbumin- sensitized and challenged mice. J Agric Food Chem 2009;

Chapkin RS, Hong MY, Fan YY, Davidson LA, Sanders LM, Henderson CE, et al. Dietary n-3 PUFA alter colonocyte mitochondrial membrane composition and function. Lipids

Chapkin RS, Kim W, Lupton JR, McMurray DN. Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. Prostaglandins Leukot

Chen H, Yu M, Li M, Zhao R, Zhu Q, Zhou W, et al. Polymorphic variations in manganese superoxide dismutase (MnSOD), glutathione peroxidase-1 (GPX1), and catalase (CAT) contribute to elevated plasma triglyceride levels in Chinese patients with type 2

diabetes or diabetic cardiovascular disease. Mol Cell Biochem 2012;363:85-91. Cheng Y, Dharancy S, Malapel M, Desreumaux P. Hepatitis C virus infection downregulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A. World J Gastroenterol 2005;11:7591-7596.

therapy for chronic hepatitis C: a prospective study. Liver Int 2009;29:248-452. Bras ML, Clément MV, Pervaiz S, Brenner C. Reactive oxygen species and the mitochondrial

signaling pathway of cell death. Histol Histopathol 2005;20:205-220.

HIV infection? HIV Med 2005;6:135-139.

1998;28:751-755.

Chem 2006; 387:1329-1335.

Clin Nutr 2006;83 (6 Suppl):1505S-1519S.

Essent Fatty Acids 2009;81:187-191.

open population study. J Hepatol 2001;34:587-592.

195.

57:10471-10476.

2002;37:193-199.

formation. Biochem Soc Trans 1993;21:330-334.

pharmaco- kinetics. Free Radic Res 2006;40:445-453.

### **Author details**

Chih-Hung Guo and Pei-Chung Chen *Micro-Nutrition Laboratory, Institute of Biomedical Nutrition, College of Medicine & Nursing, Hung-Kuang University, Taiwan, Republic of China*

### **9. References**

Bäuerle J, Laguno M, Mauss S, Mallolas J, Murillas J, Miquel R, et al. Mitochondrial DNA depletion in liver tissue of patients infected with hepatitis C virus: contributing effect of HIV infection? HIV Med 2005;6:135-139.

252 Antioxidant Enzyme

treatment.

**Author details**

**9. References**

2011;2011:530949.

2001;10:189-199.

Chih-Hung Guo and Pei-Chung Chen

*Hung-Kuang University, Taiwan, Republic of China*

disease. Pharm Biol 2011 Nov 21. [Epub ahead of print]

species. Biochemistry (Mosc) 2005;70:200-214.

induced inactivation. Oncogene 2012;31:2129-2239.

biochemical findings. Am J Gastroenterol 1999;94:2198-2205.

and a therapeutic target. Biochim Biophys Acta 2006;1762:1051-1067.

models of HCV. HCV-induced mitochondrial oxidative damage and increased ROS production facilitate HCV replication and contribute to the progression of hepatitis C. Additionally, mitochondrial dysfunction inducted by HCV reduces the b-oxidation of fatty acid and accelerates ROS formation, causing fat accumulation and hepatic lipid peroxidation. Reduced mitochondrial biogenesis also contributes to development of IR. Clinical observations indicate that therapeutic approaches targeting mitochondrial biogenesis that decrease oxidative damage and increase the response to antiviral therapy are clinically beneficial for chronic HCV-infected patients undergoing IFN-a and ribavirin

*Micro-Nutrition Laboratory, Institute of Biomedical Nutrition, College of Medicine & Nursing,*

Al-Gayyar MM, Shams ME, Barakat EA. Fish oil improves lipid metabolism and ameliorates inflammation in patients with metabolic syndrome: Impact of nonalcoholic fatty liver

Alvarez S, Valdez LB, Zaobornyj T, Boveris A. Oxygen dependence of mitochondrial nitric

Andreyev AY, Kushnareva YE, Starkov AA. Mitochondrial metabolism of reactive oxygen

Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in

Bai J, Cederbaum AI. Mitochondrial catalase and oxidative injury. Biol Signals Recept

Bakthavatchalu V, Dey S, Xu Y, Noel T, Jungsuwadee P, Holley AK, et al. Manganese superoxide dismutase is a mitochondrial fidelity protein that protects Polγ against UV-

Barbaro G, Di Lorenzo G, Asti A, Ribersani M, Belloni G, Grisorio B, et al. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and

Barber SC, Mead RJ, Shaw PJ. Oxidative stress in ALS: a mechanism of neurodegeneration

patients with non- alcoholic fatty liver disease. Clin Sci (Lond) 2004;106:635–643. Assem M, Yousri M. Impact of pentoxifylline and vitamin E on ribavirin- induced haemolytic anemia in chronic hepatitis C patients: an Egyptian survey. Int J Hepatol

oxide synthase activity. Biochem Biophys Res Commun 2003;305:771-775.

Choi J, Ou JHJ. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 2006;290:G847-G851.

Mitochondrial Free Radicals, Antioxidants, Nutrient Substances, and Chronic Hepatitis C 255

Furutani T, Hino K, Okuda M, Gondo T, Nishina S, Kitase A, et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus

Gabbay E, Zigmond E, Pappo O, Hemed N, Rowe M, Zabrecky G, et al. Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-

García-Monzón C, Majano PL, Zubia I, Sanz P, Apolinario A, Moreno-Otero R. Intrahepatic accumulation of nitrotyrosine in chronic viral hepatitis is associated with histological

Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of

Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases Hepatology 2011;54:1433-1444. Gohil VM, Greenberg ML. Mitochondrial membrane biogenesis: phospholipids and proteins

Gomez-Cabrera MC, Domenech E, Romagnoli M, Arduini A, Borras C, Pallardo FV, et al. Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training- induced adaptations in endurance performance. Am J Clin Nutr

Groenbaek K, Friis H, Hansen M, Ring-Larsen H, Krarup HB. The effect of antioxidant supplementation on hepatitis C viral load, transaminases and oxidative status: a randomized trial among chronic hepatitis C virus-infected patients. Eur J Gastroenterol

Grüngreiff K, Reinhold D. Zinc: A complementary factor in the treatment of chronic

Guo CH, Chen PC, Yeh MS, Hsiung DY, Wang CL. Cu/Zn ratios are Associated with nutritional status, oxidative stress, inflammation and immune abnormalities in patients

Guo CH, Chen PC, Lin KP, Shih MY, Ko WS. Trace metal imbalance associated with oxidative stress and inflammatory status in anti-hepatitis C virus antibody positive

Han SG, Kim Y, Kashon ML, Pack DL, Castranova V, Vallyathan V. Correlates of oxidative stress and free-radical activity in serum from asymptomatic shipyard welders. Am J

Hara Y, Hino K, Okuda M, Furutani T, Hidaka I, Yamaguchi Y, et al. Hepatitis C virus core protein inhibits deoxycholic acid-mediated apoptosis despite generating mitochondrial

blind placebo controlled clinical trial. World J Gastroenterol 2007;13:5317-5323. Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, et al. The mitochondriatargeted anti-oxidant mitoquinone decreases liver damage in a phase II study of

polyprotein. Gastroenterology 2006;130: 2087-2098.

hepatitis C patients. Liver Int 2010;30:1019-1026.

severity of liver disease. J Hepatol 2000;32:331-338.

go hand in hand. J Cell Biol 2009;184:469-472.

hepatitis C? Mol Med Report 2010;3:371-375.

Respir Crit Care Med 2005;172:1541-1548.

on peritoneal dialysis. Clin Biochem 2011;44:275-280.

subjects. Environ Toxicol Pharmacol 2012;33:288-296.

reactive oxygen species. J Gastroenterol 2006;41:257-268.

2008;87:142-149.

Hepatol 2006;18:985-989.

hepatitis C: an update. Hepatology 2009;49:1335-1374.

Furutani T, Hino K, Okuda M, Gondo T, Nishina S, Kitase A, et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006;130: 2087-2098.

254 Antioxidant Enzyme

1436.

[Epub ahead of print]

Biol Med 1996;21:291-295.

2006;163:113-132.

1995;22: 449-456.

Choi J, Ou JHJ. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 2006;290:G847-G851. Chuma M, Hige S, Nakanishi M, Ogawa K, Natsuizaka M, Yamamoto Y, et al. 8-Hydroxy-2' deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2008;23:1431-

Cimino L, Belisario MA, Intrieri M, D'Ascoli B, Sacchetti L, Salvatore F, et al. Effect of Nacetyl-cysteine on lymphomonocyte glutathione and response to interferon treatment in

Cole-Ezea P, Swan D, Shanley D, Hesketh J. Glutathione Peroxidase 4 has a major role in protecting mitochondria from oxidative damage and maintaining oxidative phosphorylation complexes in gut epithelial cells. Free Radic Biol Med 2012 May 24.

Culotta VC, Yang M, O'Halloran TV. Activation of superoxide dismutase: putting the metal

Czuczejko J, Zachara BA, Staubach-Topczewska E, Halota W, Kedziora J. Selenium, glutathione and glutathione peroxidase in blood of patients with chronic liver diseases.

De Maria N, Colantoni A, Fagiuoli S, Liu GJ, Rogers BK, Farinati F, et al. Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic

Depeint F, Bruce WR, Shangari N, Mehta R, O'Brien PJ. Mitochondrial function and toxicity: Role of B vitamins on the one-carbon transfer pathways. Chem Biol Interact

Fargion S, Fracanzani AL, Sampietro M, Molteni V, Boldorini R, Mattioli M, et al. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J

Farias MS, Budni P, Ribeiro CM, Parisotto EB, Santos CE, Dias JF, et al. Antioxidant supplementation attenuates oxidative stress in chronic hepatitis C patients.

Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol

Farinati F, Cardin R, Degan P, De Maria N, Floyd RA, Van Thiel DH, et al. Oxidative DNA damage in circulating leukocytes occurs as an early event in chronic HCV infection.

Flachs P, Horakova O, Brauner P, Rossmeisl M, Pecina P, Franssen-van Hal N, et al. Polyunsaturated fatty acids of marine origin upregulate mitochondrial biogenesis and

Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D. The ins and outs of

induce beta-oxidation in white fat. Diabetologia 2005;48:2365-2375.

mitochondrial dysfunction in NASH. Diabetes Metab 2004;30:121-138.

C-virus chronic hepatitis. Ital J Gastroenterol Hepatol 1998;30:189-193.

to pedal. Biochim Biophys Acta 2006;1763:747-758.

Acta Biochim Polon 2003; 50:1147-1154.

Gastroenterol Hepatol 1997; 9:497-503.

Free Radic Biol Med 1999; 27:1284-1291.

Gastroenterol Hepatol 2012 May 17. [Epub ahead of print]

Heuser G, Vojdani A. Enhancement of natural killer cell activity and T and B cell function by buffered vitamin C in patients exposed to toxic chemicals: the role of protein kinase-C. Immunopharmacol Immunotoxicol 1997;19:291-312.

Mitochondrial Free Radicals, Antioxidants, Nutrient Substances, and Chronic Hepatitis C 257

Khan MS, Dilawar S, Ali I, Rauf N. The possible role of selenium concentration in hepatitis B

Kira Y, Sato EF, Inoue M. Association of Cu,Zn-type superoxide dismutase with

Kirkinezos IG, Bacman SR, Hernandez D, Oca-Cossio J, Arias LJ, Perez-Pinzon MA, et al.. Cytochrome c association with the inner mitochondrial membrane is impaired in the

Kitada M, Kume S, Imaizumi N, Koya D. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in

Ko WS, Guo CH, Hsu GSW, Chiou YL, Yeh MS, Yaun SR. Effects of zinc supplementation on the treatment of chronic hepatitis C patients with interferon and ribavirin. Clin Biochem

Ko WS, Guo CH, Yeh MS, Lin LY, Hsu GS, Chen PC, et al. Blood micronutrient, oxidative stress, and viral load in patients with chronic hepatitis C. World J Gastroenterol

Kohchi C, Inagawa H, Nishizawa T, Soma G. ROS and innate immunity. Anticancer Res

Konishi M, Iwasa M, Araki J, Kobayashi Y, Katsuki A, Sumida Y, et al. Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane. J Gastroenterol Hepatol 2006;21:1821-

Korenaga M, Wang T, Li Y, Showalter LA, Chan T, Sun J, Weinman SA. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen

Korenaga M, Okuda M, Otani K, Wang T, Li Y, Weinman SA. Mitochondrial dysfunction in

Lauridsen C, Jensen SK. a-Tocopherol incorporation in mitochondria and microsomes upon supra- nutritional vitamin E supplementation. Genes Nutr 2012 Feb 22. [Epub ahead of

Lee WY, Lee JS, Lee SM. Protective effects of combined ischemic preconditioning and ascorbic acid on mitochondrial injury in hepatic ischemia/reperfusion. J Surg Res

Lenaz G, Fato R, Formiggini G, Genova ML. The role of Coenzyme Q in mitochondrial

Levent G, Ali A, Ahmet A, Polat EC, Aytaç C, Ayşe E, Ahmet S. Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after

Levine M, Padayatty SJ, Espey MG. Vitamin C: a concentration-function approach yields

Li C, Zhou HM. The role of manganese superoxide dismutase in inflammation defense.

pegylated interferon alfa-2b plus ribavirin therapy. J Transl Med 2006;4:25.

pharmacology and therapeutic discoveries. Adv Nutr 2011;2:78-88.

mitochondria and peroxisomes. Arch Biochem Biophys 2002;399:96-102.

and C patients. Saudi J Gastroenterol 2012; 18:106-110.

CNS of G93A-SOD1 mice. J Neurosci 2005;25:164-172.

2005a;38: 614-620.

2005b;11:4697-4702.

2009;29:817- 821.

1825

print]

2007;142:45-52.

Enzyme Res 2011;2011:387176.

AMPK/SIRT1- independent pathway. Diabetes 2011;60:634-643.

species (ROS) production. J Biol Chem 2005a;280:37481-37488.

hepatitis C. J Clin Gastroenterol 2005b;39(4 Suppl 2): S162-S166.

electron transport. Mitochodrion 2007;7S:S8-S33.

Khan MS, Dilawar S, Ali I, Rauf N. The possible role of selenium concentration in hepatitis B and C patients. Saudi J Gastroenterol 2012; 18:106-110.

256 Antioxidant Enzyme

Heuser G, Vojdani A. Enhancement of natural killer cell activity and T and B cell function by buffered vitamin C in patients exposed to toxic chemicals: the role of protein kinase-C.

Himoto T, Hosomi N, Nakai S, Deguchi A, Kinekawa F, Matsuki M, et al. Efficacy of zinc administration in patients with hepatitis C virus-related chronic liver disease. Scand J

Himoto T, Yoneyama H, Kurokohchi K, Inukai M, Masugata H, Goda F, et al. Selenium deficiency is associated with insulin resistance in patients with hepatitis C virus-related

Hino K, Murakami Y, Nagai A, Kitase A, Hara Y, Furutani T, et al. Alpha-tocopherol [corrected] and ascorbic acid attenuates the ribavirin [corrected] induced decrease of eicosapentaenoic acid in erythrocyte membrane in chronic hepatitis C patients. J

Ho E, Song Y.Zinc and prostatic cancer. Curr Opin Clin Nutr Metab Care 2009;12:640-645. Hoffmann PR, Berry MJ. The influence of selenium on immune responses. Mol Nutr Food

Holley AK, Bakthavatchalu V, Velez-Roman JM, St Clair DK. Manganese Superoxide

Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alphatocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology

Hübscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology

Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K, Nakamura H. Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation

Kanda T, Yokosuka O, Nagao K, Saisho H. State of hepatitis C viral replication enhances activation of NF-kB- and AP-1-signaling induced by hepatitis B virus X. Cancer Lett

Kawaguchi Y, Mizuta T, Takahashi K, Iwane S, Ario K, Kawasoe H, et al. High-dose vitamins E and C supplementation prevents ribavirin-induced hemolytic anemia in

Kawashima A, Tsukamoto I, Koyabu T, Murakami Y, Kawakami T, Kakibuchi N, et al.Eicosapentaenoic acid supplementation for chronic hepatitis C patients during combination therapy of pegylated interferon alpha-2b and ribavirin. Lipids 2008;43:325-

Kaya S, Sütüçü R, Sesli Cetin E, Cicioğlu Aridoğan B, Aktütrk O, Delibaş N. The relationship between viral load and malondialdehyde and antioxidant enzymes in patients with

Khairallah RJ, O'Shea KM, Brown BH, Khanna N, Des Rosiers C, Stanley WC. Treatment with docosa- hexaenoic acid, but not eicosapentaenoic acid, delays Ca2+-induced mitochondria permeability transition in normal and hypertrophied myocardium. J

Dismutase: Guardian of the Powerhouse. Int J Mol Sci 2011;12:7114-7162.

in chronic hepatitis C. Am J Gastroenterol 2000;95:1041-1050.

patients with chronic hepatitis C. Hepatol Res 2007;37:317-324.

hepatitis C virus infection. Mikrobiyol Bul 2006;40:55-61.

Pharmacol Exp Ther 2010;335:155-162.

Immunopharmacol Immunotoxicol 1997;19:291-312.

chronic liver disease. Nutr Res 2011;31:829-835.

Gastroenterol Hepatol 2006; 21:1269-1275.

Gastroenterol 2007;42:1078-1087.

Res 2008;52: 1273-1280.

1997;113:1069-1073.

2006;49:450- 465.

2006;234:143-148.

333.

Liang H, Van Remmen H, Frohlich V, Lechleiter J, Richardson A, Ran Q. Gpx4 protects mitochondrial ATP generation against oxidative damage. Biohem Biophys Res Commun 2007;356:893-898.

Mitochondrial Free Radicals, Antioxidants, Nutrient Substances, and Chronic Hepatitis C 259

May JM, Li L, Qu ZC, Cobb CE. Mitochondrial recycling of ascorbic acid as a mechanism for

Mecocci P, Beal MF, Cecchetti R, Polidori MC, Cherubini A, Chionne F, Avellini L, Romano G, Senin U. Mitochondrial membrane fluidity and oxidative damage to mitochondrial

Mei S, Gu H, Yang X, Guo H, Liu Z, Cao W. Prolonged exposure to insulin induces mitochondrion- derived oxidative stress through increasing mitochondrial cholesterol

Melhem A, Stern M, Shibolet O, Israeli E, Ackerman Z, Pappo O, et al. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J Clin

Merzouk H, Khan NA. Implication of lipids in macrosomia of diabetic pregnancy: can n-3 polyunsaturated fatty acids exert beneficial effects? Clin Sci 2003;105:519–529. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus- induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity.

Modica-Napolitano JS, Kulawiec M, Singh KK. Mitochondria and human cancer. Curr Mol

Montero Vega MT, de Andrés Martín A. Toll-like receptors: a family of innate sensors of danger that alert and drive immunity. Allergol Immunopathol (Madr) 2008;36:347-357. Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 2003;35:772-781. Moriya Y, Shigemizu D, Hattori M, Tokimatsu T, Kotera M, Goto S, Kanehisa M. PathPred: an enzyme-catalyzed metabolic pathway prediction server. Nucleic Acids Res 2010;38

Muller G, Morawietz H. Nitric oxide, NAD(P)H oxidase, and atherosclerosis. Antioxid

Murakami Y, Nagai A, Kawakami T, Hino K, Kitase A, Hara Y, et al. Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon alpha-2b and

Murakami Y, Koyabu T, Kawashima A, Kakibuchi N, Kawakami T, Takaguchi K, et al. Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin. J Nutr

Murthy S, Born E, Mathur S, Field FJ. 13-hydroxy octadecadienoic acid (13-HODE) inhibits triacylglycerol-rich lipoprotein secretion by CaCo-2 cells. J Lipid Res 1998;39:1254-1262. Nagamine T, Takagi H, Takayma H, Kojima A, Kakizaki S, Mori M, et al. Preliminary study of combination therapy with interferon-α and zinc in chronic hepatitis C patients with

DNA in aged and AD human brain. Mol Chem Neuropathol 1997;31:53-64.

regenerating cellular ascorbate. Biofactors 2007;30:35-48.

content in hepatocytes. Endocrinology 2012;153:2120-2129.

Gastroenterol 2005;39:737- 742.

Hepatology 2008;48: 1420-1429.

(Web Server issue):W138-43.

Redox Signal 2009;11:1711-1731.

ribavirin. Nutrition 2006;22:114-122.

Sci Vitaminol (Tokyo) 2007;53:213-218.

genotype 1b. Biol Trace Elem Res 2000;75:53-63

Med 2007;7: 121-131.

May JM, Li L, Qu ZC, Cobb CE. Mitochondrial recycling of ascorbic acid as a mechanism for regenerating cellular ascorbate. Biofactors 2007;30:35-48.

258 Antioxidant Enzyme

Commun 2007;356:893-898.

ribavirin. Clin Nutr 2009;28:34-38.

Neurosci 2005;8:67-89.

2005;280:22715-22720.

mitochondria. Free Radic Biol Med 2009;47: 312-320.

hepatosteatosis. BMC Gastroenterol 2010;10:49.

allergic murine model. J Appl Physiol 2009;107:1285-1292.

relation to substrate preference. Lipids 1999;34:951-963.

immune responses. Brit J Nutr 2007;98 (Suppl 1):S29–S35.

Antioxid Redox Signal 2004;6:19-24.

Biochem Nutr 2009;45:292- 303.

2009;484:87-93.

Liang H, Van Remmen H, Frohlich V, Lechleiter J, Richardson A, Ran Q. Gpx4 protects mitochondrial ATP generation against oxidative damage. Biohem Biophys Res

Liang H, Ran Q, Jang YC, Holstein D, Lechleiter J, McDonald-Marsh T, et al. Glutathione peroxidase 4 differentially regulates the release of apoptogenic proteins from

Lin CC, Yin MC. Vitamins B depletion, lower iron status and decreased antioxidative defense in patients with chronic hepatitis C treated by pegylated interferon alfa and

Liu J, Ames BN. Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease. Nutr

Liu J, Shen W, Zhao B, Wang Y, Wertz K, Weber P, Zhang P. Targeting mitochondrial biogenesis for preventing and treating insulin resistance in diabetes and obesity: Hope

Luk E, Yang M, Jensen LT, Bourbonnais Y, Culotta VC. Manganese activation of superoxide dismutase 2 in the mitochondria of Saccharomyces cerevisiae. J Biol Chem

Mabalirajan U, Aich J, Leishangthem GD, Sharma SK, Dinda AK, Ghosh B. Effects of vitamin E on mitochondrial dysfunction and asthma features in an experimental

Madsen L, Rustan AC, Vaagenes H, Berge K, Dyrøy E, Berge RK. Eicosapentaenoic and docosahexaenoic acid affect mitochondrial and peroxisomal fatty acid oxidation in

Maggini S, Wintergerst ES, Beveridge S, Hornig DH. Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral

Mahmood S, Kawanaka M, Kamei A, Izumi A, Nakata K, Niiyama G, et al. Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C.

Malaguarnera M, Vacante M, Giordano M, Motta M, Bertino G, Pennisi M, et al. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated

Matsuzaki S, Szweda LI, Humphries KM. Mitochondrial superoxide production and respiratory activity: biphasic response to ischemic duration. Arch Biochem Biophys

with Peg interferon-α 2b plus ribavirin. World J Gastroenterol 2011;17:4414-4420. Marchi S, Giorgi C, Suski JM, Agnoletto C, Bononi A, Bonora M, et al. Mitochondria-ros crosstalk in the control of cell death and aging. J Signal Transduct 2012;2012:329635. Matsuoka S, Matsumura H, Nakamura H, Oshiro S, Arakawa Y, Hayashi J, et al. Zinc supplementation improves the outcome of chronic hepatitis C and liver cirrhosis. J Clin

from natural mitochondrial nutrients. Adv Drug Deliv Rev 2009;61:1343-1352. Liu Q, Bengmark S, Qu S. Nutrigenomics therapy of hepatisis C virus induced-

Nagashima M, Kudo M, Chung H, Ishikawa E, Hagiwara S, Nakatani T, et al. Regulatory failure of serum prohepcidin levels in patients with hepatitis C. Hepatol Res 2006;36:288-293.

Mitochondrial Free Radicals, Antioxidants, Nutrient Substances, and Chronic Hepatitis C 261

Pereverzev MO, Vygodina TV, Konstantinov AA, Skulachev VP. Cytochrome *c*, an ideal

Petrosillo G, Ruggiero FM, Paradies G. Role of reactive oxygen species and cardiolipin in the

Phung CD, Ezieme JA, Turrens JF. Hydrogen peroxide metabolism in skeletal muscle

Piccoli C, Scrima R, Quarato G, D'Aprile A, Ripoli M, Lecce L, et al. Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-

Pillai AA, Lee VS, Wang E, Rinella ME, Levitsky J. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C. Transplant

Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by

Prasad AS. Zinc in human health: effect of zinc on immune cells. Mol Med 2008;14:353-357. Prasad AS. Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin

Quarato G, D'Aprile A, Gavillet B, Vuagniaux G, Moradpour D, Capitanio N, et al. The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial

Reiman RM, Thompson RW, Feng CG, Hari D, Knight R, Cheever AW. Interleukin-5 (IL-5) augments the progression of liver fibrosis by regulating IL-13 activity. Infect Immun

Roca B, Bennasar M, Ferrero JA, del Monte MC, Resino E. Hepatitis C virus co-infection and sexual risk behaviour are associated with a high homocysteine serum level in HIV-

Rodríguez-Rodríguez E, Bermejo LM, López-Sobaler AM, Ortega RM. An inadequate intake of manganese may favour insulin resistance in girls. Nutr Hosp 2011;26:965-970. Roe B, Kensicki E, Mohney R, Hall WW. Metabolomic profile of hepatitis C virus-infected

Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of

Romano M, Vacante M, Cristaldi E, Colonna V, Gargante MP, Cammalleri L, et al. Lcarnitine treatment reduces steatosis in patients with chronic hepatitis C treated with

Rosa EF, Ribeiro RF, Pereira FM, Freymüller E, Aboulafia J, Nouailhetas VL. Vitamin C and E supplementation prevents mitochondrial damage of ileum myocytes caused by

Rosenberg P, Hagen K. Serum B12 levels predict response to treatment with interferon and ribavirin in patients with chronic HCV infection. J Viral Hepat 2011;18:129-134.

intense and exhaustive exercise training. J Appl Physiol 2009;107:1532-1538.

Rink L, Haase H. Zinc homeostasis and immunity. Trends Immuol 2007;28:1-4.

nonalcoholic steatohepatitis. Free Radic Biol Med 2012;52:59-69.

alpha-interferon and ribavirin. Dig Dis Sci 2008;53:1114-1121.

release of cytochrome c from mitochondria. FASEB J 2003;17:2202-2208.

antioxidant. Biochem Soc Trans 2003;31(Pt 6):1312-1315.

mitochondria. Arch Biochem Biophys 1994;315:479-482.

standardized Silymarin. Gastroenterology 2007;132:1925-1936.

oxidative stress. Hepatology 2007;46:58-65.

Clin Nutr Metab Care 2009;12:646-652.

hepatocytes. PLoS One 2011;6:e23641.

dysfunction. Hepatology 2012;55:1333-1343.

infected patients. Swiss Med Wkly 2012;141:w13323.

Proc 2010;42:3647- 3651.

2006;74:1471-1479.

Pereverzev MO, Vygodina TV, Konstantinov AA, Skulachev VP. Cytochrome *c*, an ideal antioxidant. Biochem Soc Trans 2003;31(Pt 6):1312-1315.

260 Antioxidant Enzyme

2006;36:288-293.

2000;42:187-192.

1998;45:797-804.

2012;340:330-338.

2009;67:427-438

death. Apoptosis 2007;12:913-922.

Clin Biochem 2005;38: 700-705.

protein. Gastroenterology 2002;12:366-375.

death. Annu Rev Pharmacol Toxicol 2007;47:143-183.

Nagashima M, Kudo M, Chung H, Ishikawa E, Hagiwara S, Nakatani T, et al. Regulatory failure of serum prohepcidin levels in patients with hepatitis C. Hepatol Res

Naoi M, Maruyama W. Monoamine oxidase inhibitors as neuroprotective agents in agedependent neurodegenerative disorders. Curr Pharm Des 2010;16:2799-2817. Narasimhan S, Gokulakrishnan K, Sampathkumar R, Farooq S, Ravikumar R, Mohan V, et al. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem 2010;43:815-21. Neri S, Ierna D, Antoci S, Campanile E, D'Amico RA, Noto R. Association of alphainterferon and acetyl cysteine in patients with chronic C hepatitis. Panminerva Med

Niederau C, Strohmeyer G, Heintges T, Peter K, Göpfert E. Polyunsaturated phosphatidylcholine and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double- blind, placebo-controlled trial. Hepatogastroenterology

Nowak G, Bakajsova D, Hayes C, Hauer-Jensen M, Compadre CM. γ-Tocotrienol protects against mitochondrial dysfunction and renal cell death. J Pharmacol Exp Ther

Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core

Onoda H, Takahashi H, Osada M, Saito A, Zeniya M, Toda G. The relationship between the intracellular redox status of immune cells and progression of hepatitis C virus related

Orrenius S, Gogvadze V, Zhivotovsky B. Mitochondrial oxidative stress: implications for cell

Orsucci D, Filosto M, Siciliano G, Mancuso M. Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction. Nutr Rev

O'Shea KM, Khairallah RJ, Sparagna GC, Xu W, Hecker PA, Robillard-Frayne I, et al. Dietary omega-3 fatty acids alter cardiac mitochondrial phospholipid composition and delay

Ott M, Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria, oxidative stress and cell

Paradies G, Petrosillo G, Pistolese M, Di Venosa N, Federici A, Ruggiero FM. Decrease in mitochondrial complex I activity in ischemic/reperfused rat heart: involvement of

Pawlak K, Pawlak D, Mysliwiec M. Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease.

Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: A cure and so much more. Clin Infect Dis 2011;52:889-900.

chronic liver disease. Nihon Rinsho Meneki Gakkai Kaishi 2004;27:315-21.

Ca2+-induced permeability transition. J Mol Cell Cardiol 2009;47:819-827.

reactive oxygen species and cardiolipin. Circ Res 2004;94:53-59.

Rosenfeldt F, Marasco S, Lyon W, Wowk M, Sheeran F, Bailey M, et al. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J Thorac Cardiovasc Surg 2005;129:25-32.

Mitochondrial Free Radicals, Antioxidants, Nutrient Substances, and Chronic Hepatitis C 263

Takamiya R, Takahashi M, Myint T, Park YS, Miyazawa N, Endo T, et al. Glycation proceeds faster in mutated Cu, Zn-superoxide dismutases related to familial amyotrophic lateral

Tarnopolsky MA. The mitochondrial cocktail: rationale for combined nutraceutical therapy

Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM. The NS5A protein of hepatitis

Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung

Thorén F, Romero A, Lindh M, Dahlgren C, Hellstrand K. A hepatitis C virus-encoded, nonstructural protein (NS3) triggers dysfunction and apoptosis in lymphocytes: role of

Tinahones FJ, Murri-Pierri M, Garrido-Sánchez L, García-Almeida JM, García-Serrano S, García-Arnés J, et al. Oxidative stress in severely obese persons is greater in those with

Tomioka K, Kakibuchi N, Murakami Y, Kawakami T, Takaguchi K, Kita K, et al. Effects of eicosa- pentaenoic acid supplementation in the treatment of chronic hepatitis C

Van Houten B, Woshner V, Santos JH. Role of mitochondrial DNA in toxic responses to

Vidali M, Stewart SF, Albano E. Interplay between oxidative stress and immunity in the

Wang ZB, Li M, Zhao Y, Xu JX. Cytochrome C is a hydrogen peroxide scavenger in

Wang B, Zhu H, Sun H, Pan J, Yuan Z, Yu R. Plasma 8-isoprostane concentrations in

Wen JJ, Yachelini PC, Sembaj A, Manzur RE, Garg NJ. Increased oxidative stress is correlated with mitochondrial dysfunction in chagasic patients. Free Radic Biol Med

West AP, Shadel GS, Ghosh S. Mitochondria in innate immune responses. Nat Rev Immunol

Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 1996;313 (Pt 1):17-29. Wiswedel I, Hirsch D, Nourooz-Zadeh J, Flechsig A, Lück-Lambrecht A, Augustin W. Analysis of monohydroxyeicosatetraenoic acids and F2-isoprostanes as markers of lipid

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, et al. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin

Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and

progression of alcohol-mediated liver injury. Trends Mol Med 2008;14:63-71.

patients with age-related cataracts. Clin Chem 2005;51:1541-1544.

peroxidation in rat brain mitochondria. Free Radic Res 2002;36:1-11.

NADPH oxidase-derived oxygen radicals. J Leukoc Biol 2004;76:1180-1186.

in mitochondrial cytopathies. Adv Drug Rev 2008;60:1561-1567.

C virus is a zinc metalloprotein. J Biol Chem 2004;279:48576-48587.

sclerosis. FASEB J 2003;17:938-940.

Cell Mol Physiol 2000;279:L1005-L1028.

insulin resistance. Obesity 2009;17:240-246.

patients. J Nutr Sci Vitaminol (Tokyo) 2005;51:419-425.

oxidative stress. DNA Repair (Amst) 2006;5:145-152.

mitochondria. Protein Pept Lett 2003;10:247-253.

2006;41:270-276.

2011;11: 389-402.

Drug Investig 2008;28:9-16.

Takamiya R, Takahashi M, Myint T, Park YS, Miyazawa N, Endo T, et al. Glycation proceeds faster in mutated Cu, Zn-superoxide dismutases related to familial amyotrophic lateral sclerosis. FASEB J 2003;17:938-940.

262 Antioxidant Enzyme

2009;2:27-35.

tissue. Lipids 2004;39:1177- 1185.

FASEB J 2005;19:1657-1667.

2010;4:782-793.

Soc 2005;70:601-608.

Hepat 2001;8:367-371.

extremities Fiziol Zh 2008; 54:47-51.

Allergol Immunopathol (Madr) 2011;39:200-205.

alcoholic liver. Free Radic Biol Med 2007;43:869-882.

young adults. Am J Clin Nutr 2007;85:173-181.

Rosenfeldt F, Marasco S, Lyon W, Wowk M, Sheeran F, Bailey M, et al. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro

Russo AJ. Decreased serum Cu/Zn SOD in children with Autism. Nutr Metabol Insights

Russo AJ. Decreased Serum Cu/Zn SOD Associated with high copper in children with attention deficit hyperactivity disorder (ADHD). J Central Nerv Sys Dis 2010;2:9-14. Ruzickova J, Rossmeisl M, Prazak T, Flachs P, Sponarova J, Veck M. Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose

Sagdic A, Senerb O, Bulucua F, Karadurmusa N, Özelc HE, Yamaneld L et al. Oxidative stress status and plasma trace elements in patients with asthma orallergicrhinitis.

Sagun KC, Cárcamo JM, Golde DW. Vitamin C enters mitochondria via facilitative glucose transporter 1 (Glut1) and confers mitochondrial protection against oxidative injury.

Sahach VF, Kakhanovs'kyŭ EF, Horbovets' VS. The mitochondrial permeability transition pore opening under oxidative stress in ischemia/reperfusion in the tissue of the lower

Siler-Marsiglio KI, Pan Q, Paiva M, Madorsky I, Khurana NC, Heaton MB. Mitochondrially targeted vitamin E and vitamin E mitigate ethanol-mediated effects on cerebellar

Simula MP, De Re V. Hepatitis C virus-induced oxidative stress and mitochondrial dysfunction: a focus on recent advances in proteomics. Proteomics Clin Appl

Song Y, Leonard SW, Traber MG, Ho E. Zinc deficiency affects DNA damage, oxidative stress, antioxidant defenses, and DNA repair in rats. J Nutr 2009;139:1626-1631. Stephensen CB, Marquis GS, Douglas SD, Kruzich LA, Wilson CM. Glutathione, glutathione peroxidase, and selenium status in HIV-positive and HIV-negative adolescents and

Stojanovi S, Dragani S, Milan N, Smiljana R, Mihajlo S, and Vesna N. Manganese superoxide dismutase (MnSOD) catalyzes NO-dependent tyrosine residue nitration. J Serb Chem

Suzuki H, Takagi H, Sohara N, Kanda D, Kakizaki S, Sato K, et al. Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial. World J Gastroenterol 2006;12:1265-1269. Takagi H, Nagamine T, Abe T, Takayama H, Sato K, Otsuka T, et al. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. J Viral

Saper RB, Rash R. Zinc: An essential micronutrient. Am Fam Physician 2009; 79:768-772. Seronello S, Sheikh MY, Choi J. Redox regulation of hepatitis C in non-alcoholic and

granule cell antioxidant defense systems. Brain Res 2005;1052:202-211.

contractility of myocardial tissue. J Thorac Cardiovasc Surg 2005;129:25-32.

improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 2001;50:411-417.

**Chapter 10**

© 2012 Kulbacka et al., licensee InTech. This is an open access chapter distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

© 2012 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,

**Apoptosis, Free Radicals and**

Anna Choromańska and Nina Skołucka

http://dx.doi.org/10.5772/50357

nor are they widely accepted.

**1. Introduction**

Additional information is available at the end of the chapter

**Antioxidant Defense in Antitumor Therapy**

Tumor markers are measurable biochemicals that are associated with a malignancy. They are either produced by tumor cells (tumor-derived) or by the body in response to tumor cells (tumor-associated). They are usually substances that are released into the circulation and then measured in the blood sample. There are a few exceptions to this, such as tissuebound receptors that must be measured in a biopsy from the solid tumor or proteins that are secreted into the urine. Despite the fact that tumor markers are hardly ever specific enough to be used alone to diagnose cancer, they do have a number of clinical applications. They can be used to stage cancer, to indicate a prognosis, to monitor treatment, or in follow-up to watch for cancer recurrence. Changes in some tumor markers have been sensitive enough to be used as targets in clinical trials. Tumor markers for diagnosis are used in combination with other clinical parameters such as biopsy and radiological findings. Although there are a multitude of tumor markers, very few of them have found their way into clinical practice because of their lack of specificity. However, some of these non-specific markers have found

Tumor marker discovering is focuses currently much research and attention. Their final clinical usage is directed by approval from the Food and Drug Administration (FDA) and guidelines established by organizations such as the American Society of Clinical Oncology and the American Cancer Society. Not all tumor receptor marker tests are widely available

In the current review we attempt to propose and bring closer some new "cancer markers" connected to oxidative stress and cell death. In recent times, therapeutic approaches take advantages from determination of oxidative stress markers. These markers have gained importance in the evaluation of cancer treatment and prognosis. In this chapter we try to

and reproduction in any medium, provided the original work is properly cited.

Julita Kulbacka, Jolanta Saczko, Agnieszka Chwilkowska,

a place in monitoring cancer treatment rather than in diagnosis.

### **Apoptosis, Free Radicals and Antioxidant Defense in Antitumor Therapy**

Julita Kulbacka, Jolanta Saczko, Agnieszka Chwilkowska, Anna Choromańska and Nina Skołucka

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/50357

### **1. Introduction**

264 Antioxidant Enzyme

2007;102:103-112.

Res 1999;70:97-116.

activation. Diabetes 2001;50:411-417.

review. Biochim Biophys Acta 2006;1757:509-517.

improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma

Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, et al. Obesity and nonalcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004;38:705-709. Zang Q, Maass DL, White J, Horton JW. Cardiac mitochondrial damage and loss of ROS defense after burn injury: the beneficial effects of antioxidant therapy. J Appl Physiol

Zhang W, Ramanathan CS, Nadimpalli RG, Bhat AA, Cox AG, Taylor EW. Seleniumdependent glutathione peroxidase modules encoded by RNA viruses. Biol Trace Elem

Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-induced ROS release: an update and

Tumor markers are measurable biochemicals that are associated with a malignancy. They are either produced by tumor cells (tumor-derived) or by the body in response to tumor cells (tumor-associated). They are usually substances that are released into the circulation and then measured in the blood sample. There are a few exceptions to this, such as tissuebound receptors that must be measured in a biopsy from the solid tumor or proteins that are secreted into the urine. Despite the fact that tumor markers are hardly ever specific enough to be used alone to diagnose cancer, they do have a number of clinical applications. They can be used to stage cancer, to indicate a prognosis, to monitor treatment, or in follow-up to watch for cancer recurrence. Changes in some tumor markers have been sensitive enough to be used as targets in clinical trials. Tumor markers for diagnosis are used in combination with other clinical parameters such as biopsy and radiological findings. Although there are a multitude of tumor markers, very few of them have found their way into clinical practice because of their lack of specificity. However, some of these non-specific markers have found a place in monitoring cancer treatment rather than in diagnosis.